

References

Kidney International Supplements (2013) **3**, 136–150; doi:10.1038/kisup.2012.72

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; **39**: S1–266.
2. Astor BC, Matsushita K, Gansevoort RT *et al*. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011; **79**: 1331–1340.
3. Gansevoort RT, Matsushita K, Coresh J *et al*. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011; **80**: 93–104.
4. Matsushita K, van der Velde M, Astor BC *et al*. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; **375**: 2073–2081.
5. van der Velde M, Matsushita K, Coresh J *et al*. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011; **79**: 1341–1352.
6. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. *Am J Kidney Dis* 2009; **53**: S4–16.
7. KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney inter., Suppl.* 2012; **2**: 1–138.
8. KDIGO GN Work Group. KDIGO clinical practice guideline for glomerulonephritis. *Kidney inter., Suppl.* 2012; **2**: 139–274.
9. KDIGO CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2009; **76**(Suppl 113): S1–130.
10. KDIGO BP Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney inter., Suppl.* 2012; **2**: 337–414.
11. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney inter., Suppl.* 2012; **2**: 279–335.
12. Herzog CA, Asinger RW, Berger AK *et al*. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2011; **80**: 572–586.
13. Matzke GR, Aronoff GR, Atkinson AJ, Jr. *et al*. Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2011; **80**: 1122–1137.
14. Hsu CY, Ordonez JD, Chertow GM *et al*. The risk of acute renal failure in patients with chronic kidney disease. *Kidney Int* 2008; **74**: 101–107.
15. Hailpern SM, Melamed ML, Cohen HW *et al*. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). *J Am Soc Nephrol* 2007; **18**: 2205–2213.
16. James MT, Hemmelgarn BR, Wiebe N *et al*. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. *Lancet* 2010; **376**: 2096–2103.
17. James MT, Quan H, Tonelli M *et al*. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney Dis* 2009; **54**: 24–32.
18. Wilhelm-Leen ER, Hall YN, M KT *et al*. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. *Am J Med* 2009; **122**: 664–671 e662.
19. Levey AS, Coresh J. Chronic kidney disease. *Lancet* 2012; **379**: 165–180.
20. Wesson L. Physiology of the human kidney. Grune & Stratton: New York, 1969.
21. Rowe JW, Andres R, Tobin JD. Letter: Age-adjusted standards for creatinine clearance. *Ann Intern Med* 1976; **84**: 567–569.
22. Poggio ED, Rule AD, Tanchanco R *et al*. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. *Kidney Int* 2009; **75**: 1079–1087.
23. Rule AD, Amer H, Cornell LD *et al*. The association between age and nephrosclerosis on renal biopsy among healthy adults. *Ann Intern Med* 2010; **152**: 561–567.
24. Barai S, Gambhir S, Prasad N *et al*. Levels of GFR and protein-induced hyperfiltration in kidney donors: a single-center experience in India. *Am J Kidney Dis* 2008; **51**: 407–414.
25. Eastwood JB, Kerry SM, Plange-Rhule J *et al*. Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations. *Nephrol Dial Transplant* 2010; **25**: 2178–2187.
26. Jafar TH, Islam M, Jessani S *et al*. Level and determinants of kidney function in a South Asian population in Pakistan. *Am J Kidney Dis* 2011; **58**: 764–772.
27. Stevens LA, Coresh J, Greene T *et al*. Assessing kidney function—measured and estimated glomerular filtration rate. *N Engl J Med* 2006; **354**: 2473–2483.
28. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest* 2006; **116**: 288–296.
29. KDIGO Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant* 2009; **9** (Suppl 3): S1–155.
30. Levey AS, de Jong PE, Coresh J *et al*. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011; **80**: 17–28.
31. Levey AS, Eckardt KU, Tsukamoto Y *et al*. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; **67**: 2089–2100.
32. Eckardt KU, Berns JS, Rocco MV *et al*. Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. *Am J Kidney Dis* 2009; **53**: 915–920.
33. Eknoyan G. Chronic kidney disease definition and classification: no need for a rush to judgment. *Kidney Int* 2009; **75**: 1015–1018.
34. El Nahas M. Cardio-Kidney-Damage: a unifying concept. *Kidney Int* 2010; **78**: 14–18.
35. Levey AS, Astor BC, Stevens LA *et al*. Chronic kidney disease, diabetes, and hypertension: what's in a name? *Kidney Int* 2010; **78**: 19–22.
36. Winearls CG, Glasscock RJ. Dissecting and refining the staging of chronic kidney disease. *Kidney Int* 2009; **75**: 1009–1014.
37. Silva FG. The aging kidney: a review – part I. *Int Urol Nephrol* 2005; **37**: 185–205.
38. Silva FG. The aging kidney: a review—part II. *Int Urol Nephrol* 2005; **37**: 419–432.
39. Weinstein JR, Anderson S. The aging kidney: physiological changes. *Adv Chronic Kidney Dis* 2010; **17**: 302–307.
40. King AJ, Levey AS. Dietary protein and renal function. *J Am Soc Nephrol* 1993; **3**: 1723–1737.
41. Vehaskari VM. Orthostatic proteinuria. *Arch Dis Child* 1982; **57**: 729–730.
42. Seikaly MG, Ho PL, Emmett L *et al*. Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. *Pediatr Nephrol* 2003; **18**: 796–804.
43. Hogg RJ, Furth S, Lemley KV *et al*. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics* 2003; **111**: 1416–1421.
44. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. *Pediatr Clin North Am* 1987; **34**: 571–590.
45. Aperia A, Broberger O, Elinder G *et al*. Postnatal development of renal function in pre-term and full-term infants. *Acta Paediatr Scand* 1981; **70**: 183–187.
46. Bueva A, Guignard JP. Renal function in preterm neonates. *Pediatr Res* 1994; **36**: 572–577.
47. Fetterman GH, Shuplock NA, Philipp FJ *et al*. The Growth and Maturation of Human Glomeruli and Proximal Convolutions from Term to Adulthood: Studies by Microdissection. *Pediatrics* 1965; **35**: 601–619.
48. Guignard JP, Torrado A, Da Cunha O *et al*. Glomerular filtration rate in the first three weeks of life. *J Pediatr* 1975; **87**: 268–272.
49. Haycock GB. Development of glomerular filtration and tubular sodium reabsorption in the human fetus and newborn. *Br J Urol* 1998; **81** (Suppl 2): 33–38.
50. Gallini F, Maggio L, Romagnoli C *et al*. Progression of renal function in preterm neonates with gestational age < or = 32 weeks. *Pediatr Nephrol* 2000; **15**: 119–124.

51. Vieux R, Hascoet JM, Merdarius D *et al*. Glomerular filtration rate reference values in very preterm infants. *Pediatrics* 2010; **125**: e1186-1192.
52. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. *Pediatr Nephrol* 2007; **22**: 1839-1848.
53. Waters AM. Chapter 6, Part 2: Functional development of the nephron. In: Geary DF, Schaefer F (eds). *Comprehensive Pediatric Nephrology*, Mosby Elsevier: Philadelphia, PA, 2008, pp 111-129.
54. Langlois V. Chapter 2: Laboratory evaluation at different ages. In: Geary DF, Schaefer F (eds) *Comprehensive Pediatric Nephrology*, Mosby Elsevier: Philadelphia, PA, 2008, pp 39-54.
55. Furth SL, Cole SR, Moxey-Mims M *et al*. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. *Clin J Am Soc Nephrol* 2006; **1**: 1006-1015.
56. Copelovitch L, Warady BA, Furth SL. Insights from the Chronic Kidney Disease in Children (CKiD) study. *Clin J Am Soc Nephrol* 2011; **6**: 2047-2053.
57. Seliger SL, Zhan M, Hsu VD *et al*. Chronic kidney disease adversely influences patient safety. *J Am Soc Nephrol* 2008; **19**: 2414-2419.
58. Go AS, Chertow GM, Fan D *et al*. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; **351**: 1296-1305.
59. Coresh J, Astor BC, Greene T *et al*. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; **41**: 1-12.
60. Burgert TS, Dziura J, Yeckel C *et al*. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. *Int J Obes (Lond)* 2006; **30**: 273-280.
61. Csernus K, Lanyi E, Erhardt E *et al*. Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. *Eur J Pediatr* 2005; **164**: 44-49.
62. Houser MT, Jahn MF, Kobayashi A *et al*. Assessment of urinary protein excretion in the adolescent: effect of body position and exercise. *J Pediatr* 1986; **109**: 556-561.
63. Trachtenberg F, Barregard L. The effect of age, sex, and race on urinary markers of kidney damage in children. *Am J Kidney Dis* 2007; **50**: 938-945.
64. Brem AS. Neonatal hematuria and proteinuria. *Clin Perinatol* 1981; **8**: 321-332.
65. Hogg RJ, Portman RJ, Milliner D *et al*. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). *Pediatrics* 2000; **105**: 1242-1249.
66. Jones CA, Francis ME, Eberhardt MS *et al*. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2002; **39**: 445-459.
67. Levey AS, Coresh J. Should the K/DOQI definition of chronic kidney disease be changed? *Am J Kidney Dis* 2003; **42**: 626-630.
68. Uhlig K, Levey AS. Developing guidelines for chronic kidney disease: we should include all of the outcomes. *Ann Intern Med* 2012; **156**: 599-601.
69. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 Annual Report. (<https://web.emmes.com/study/ped/annrpt/Annual%20Report%20-2008.pdf>). Accessed September 7, 2012.
70. Ardisino G, Dacco V, Testa S *et al*. Epidemiology of chronic renal failure in children: data from the Italkid project. *Pediatrics* 2003; **111**: e382-387.
71. Pierce CB, Cox C, Saland JM *et al*. Methods for characterizing differences in longitudinal glomerular filtration rate changes between children with glomerular chronic kidney disease and those with nonglomerular chronic kidney disease. *Am J Epidemiol* 2011; **174**: 604-612.
72. Furth SL, Abraham AG, Jerry-Fluker J *et al*. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 2132-2140.
73. Wingan AM, Fabian-Bach C, Schaefer F *et al*. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. *Lancet* 1997; **349**: 1117-1123.
74. Staples AO, Greenbaum LA, Smith JM *et al*. Association between clinical risk factors and progression of chronic kidney disease in children. *Clin J Am Soc Nephrol* 2010; **5**: 2172-2179.
75. Ardisino G, Testa S, Dacco V *et al*. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Italkid Project. *Pediatr Nephrol* 2004; **19**: 172-177.
76. Wong CS, Pierce CB, Cole SR *et al*. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. *Clin J Am Soc Nephrol* 2009; **4**: 812-819.
77. Ardisino G, Testa S, Dacco V *et al*. Puberty is associated with increased deterioration of renal function in patients with CKD: data from the Italkid Project. *Arch Dis Child* 2012; **97**: 885-888.
78. Querfeld U, Anarat A, Bayazit AK *et al*. The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. *Clin J Am Soc Nephrol* 2010; **5**: 1642-1648.
79. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. *J Am Soc Nephrol* 2009; **20**: 2305-2313.
80. Schwartz GJ, Munoz A, Schneider MF *et al*. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 2009; **20**: 629-637.
81. Myers GL, Miller WG, Coresh J *et al*. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clin Chem* 2006; **52**: 5-18.
82. Miller WG. Estimating glomerular filtration rate. *Clin Chem Lab Med* 2009; **47**: 1017-1019.
83. Kilpatrick ES, Verrill H. A national audit of estimated glomerular filtration rate and proteinuria reporting in the UK. *Ann Clin Biochem* 2011; **48**: 558-561.
84. McIntosh JF, Moller E, Van Slyke DD. Studies of urea excretion. III: The influence of body size on urea output. *J Clin Invest* 1928; **6**: 467-483.
85. Earley A, Miskulin D, Lamb EJ *et al*. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. *Ann Intern Med* 2012; **156**: 785-795.
86. Levey AS, Coresh J, Greene T *et al*. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med* 2006; **145**: 247-254.
87. Levey AS, Stevens LA, Schmid CH *et al*. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**: 604-612.
88. Horio M, Imai E, Yasuda Y *et al*. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. *Am J Kidney Dis* 2010; **56**: 32-38.
89. Imai E, Horio M, Nitta K *et al*. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007; **11**: 41-50.
90. Praditpornsilpa K, Townamchai N, Chaiwatanarat T *et al*. The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. *Nephrol Dial Transplant* 2011; **26**: 2780-2785.
91. Matsuo S, Imai E, Horio M *et al*. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009; **53**: 982-992.
92. Levey AS, Greene T, Kusek J *et al*. A simplified equation to predict glomerular filtration rate from serum creatinine. *J Am Soc Nephrol* 2000; **11**: 155A.
93. Ma YC, Zuo L, Chen JH *et al*. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; **17**: 2937-2944.
94. Levey AS, Bosch JP, Lewis JB *et al*. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; **130**: 461-470.
95. Murata K, Baumann NA, Saenger AK *et al*. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. *Clin J Am Soc Nephrol* 2011; **6**: 1963-1972.
96. Lane BR, Demirjian S, Weight CJ *et al*. Performance of the chronic kidney disease-epidemiology study equations for estimating glomerular filtration rate before and after nephrectomy. *J Urol* 2010; **183**: 896-901.
97. Michels WM, Grootendorst DC, Verduijn M *et al*. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J Am Soc Nephrol* 2010; **5**: 1003-1009.
98. Tent H, Rook M, Stevens LA *et al*. Renal function equations before and after living kidney donation: a within-individual comparison of performance at different levels of renal function. *Clin J Am Soc Nephrol* 2010; **5**: 1960-1968.
99. Kukla A, El-Shahawi Y, Leister E *et al*. GFR-estimating models in kidney transplant recipients on a steroid-free regimen. *Nephrol Dial Transplant* 2010; **25**: 1653-1661.
100. White CA, Akbari A, Doucette S *et al*. Estimating glomerular filtration rate in kidney transplantation: is the new chronic kidney disease epidemiology collaboration equation any better? *Clin Chem* 2010; **56**: 474-477.
101. Poge U, Gerhardt T, Stoffel-Wagner B *et al*. Validation of the CKD-EPI formula in patients after renal transplantation. *Nephrol Dial Transplant* 2011; **26**: 4104-4108.

102. Jones GR, Imam SK. Validation of the revised MDRD formula and the original Cockcroft and Gault formula for estimation of the glomerular filtration rate using Australian data. *Pathology* 2009; **41**: 379-382.
103. Jones GR. Use of the CKD-EPI equation for estimation of GFR in an Australian cohort. *Pathology* 2010; **42**: 487-488.
104. Cirillo M, Lombardi C, Luciano MG *et al.* Estimation of GFR: a comparison of new and established equations. *Am J Kidney Dis* 2010; **56**: 802-804.
105. Eriksen BO, Mathisen UD, Melsom T *et al.* Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. *Kidney Int* 2010; **78**: 1305-1311.
106. Redal-Baigorri B, Stokholm KH, Rasmussen K *et al.* Estimation of kidney function in cancer patients. *Dan Med Bull* 2011; **58**: A4236.
107. Matsushita K, Mahmoodi BK, Woodward M *et al.* Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. *JAMA* 2012; **307**: 1941-1951.
108. Rule AD, Teo BW. GFR estimation in Japan and China: what accounts for the difference? *Am J Kidney Dis* 2009; **53**: 932-935.
109. Stevens LA, Claybon MA, Schmid CH *et al.* Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. *Kidney Int* 2011; **79**: 555-562.
110. Yeo Y, Han DJ, Moon DH *et al.* Suitability of the IDMS-traceable MDRD equation method to estimate GFR in early postoperative renal transplant recipients. *Nephron Clin Pract* 2010; **114**: c108-117.
111. van Deventer HE, George JA, Paiker JE *et al.* Estimating glomerular filtration rate in black South Africans by use of the modification of diet in renal disease and Cockcroft-Gault equations. *Clin Chem* 2008; **54**: 1197-1202.
112. Teo BW, Xu H, Wang D *et al.* GFR estimating equations in a multiethnic Asian population. *Am J Kidney Dis* 2011; **58**: 56-63.
113. Inker LA, Schmid CH, Tighiouart H *et al.* Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012; **367**: 20-29.
114. Peralta CA, Shlipak MG, Judd S *et al.* Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. *JAMA* 2011; **305**: 1545-1552.
115. Schwartz GJ, Schneider MF, Maier PS *et al.* Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. *Kidney Int* 2012; **82**: 445-453.
116. Inker LA, Eckfeldt J, Levey AS *et al.* Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. *Am J Kidney Dis* 2011; **58**: 682-684.
117. Stevens LA, Coresh J, Schmid CH *et al.* Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J Kidney Dis* 2008; **51**: 395-406.
118. Zappitelli M, Parvex P, Joseph L *et al.* Derivation and validation of cystatin C-based prediction equations for GFR in children. *Am J Kidney Dis* 2006; **48**: 221-230.
119. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? *Pediatr Nephrol* 2003; **18**: 981-985.
120. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. *Nephrol Dial Transplant* 2003; **18**: 2024-2031.
121. Kwong YT, Stevens LA, Selvin E *et al.* Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. *Am J Kidney Dis* 2010; **56**: 39-49.
122. Lamb EJ, Price CP. Kidney function tests. In: Burtis CA, Ashwood E, (eds.) *Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*, 5th edition, Elsevier, 2012, pp 669-708.
123. Ballantyne FC, Gibbons J, O'Reilly DS. Urine albumin should replace total protein for the assessment of glomerular proteinuria. *Ann Clin Biochem* 1993; **30** (Pt 1): 101-103.
124. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? *Ann Clin Biochem* 2009; **46**: 205-217.
125. Newman DJ, Thakkar H, Medcalf EA *et al.* Use of urine albumin measurement as a replacement for total protein. *Clin Nephrol* 1995; **43**: 104-109.
- 125a. Hallan SI, Ritz E, Lydersen S *et al.* Combining GFR and albuminuria to classify CKD improves prediction of ESRD. *J Am Soc Nephrol* 2009; **20**: 1069-1077.
- 125b. Brantsma AH, Bakker SJ, Hillege HL *et al.* Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. *Nephrol Dial Transplant* 2008; **23**: 3851-3858.
126. Dawanay A, Wilson AG, Lamb E *et al.* Microalbuminuria in systemic sclerosis. *Ann Rheum Dis* 1992; **51**: 384-388.
127. Gross JL, de Azevedo MJ, Silveiro SP *et al.* Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* 2005; **28**: 164-176.
128. Ninomiya T, Perkovic V, de Galan BE *et al.* Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol* 2009; **20**: 1813-1821.
129. Shihabi ZK, Konecny JC, O'Connor ML. Albuminuria vs urinary total protein for detecting chronic renal disorders. *Clin Chem* 1991; **37**: 621-624.
130. Martin H. Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. *Clin Biochem Rev* 2011; **32**: 97-102.
131. Waugh J, Bell SC, Kilby M *et al.* Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies. *Hypertens Pregnancy* 2001; **20**: 205-217.
132. Waugh J, Bell SC, Kilby MD *et al.* Urine protein estimation in hypertensive pregnancy: which thresholds and laboratory assay best predict clinical outcome? *Hypertens Pregnancy* 2005; **24**: 291-302.
133. McElderry LA, Tarbit IF, Cassells-Smith AJ. Six methods for urinary protein compared. *Clin Chem* 1982; **28**: 356-360.
134. Nishi HH, Elin RJ. Three turbidimetric methods for determining total protein compared. *Clin Chem* 1985; **31**: 1377-1380.
135. Sedmak JJ, Grossberg SE. A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. *Anal Biochem* 1977; **79**: 544-552.
136. de Keijzer MH, Klases IS, Branten AJ *et al.* Infusion of plasma expanders may lead to unexpected results in urinary protein assays. *Scand J Clin Lab Invest* 1999; **59**: 133-137.
137. Marshall T, Williams KM. Extent of aminoglycoside interference in the pyrogallol red-molybdate protein assay depends on the concentration of sodium oxalate in the dye reagent. *Clin Chem* 2004; **50**: 934-935.
138. Yilmaz FM, Yucler D. Effect of addition of hemolysate on urine and cerebrospinal fluid assays for protein. *Clin Chem* 2006; **52**: 152-153.
139. Chambers RE, Bullock DG, Whicher JT. External quality assessment of total urinary protein estimation in the United Kingdom. *Ann Clin Biochem* 1991; **28** (Pt 5): 467-473.
140. Heick HM, Begin-Heick N, Acharya C *et al.* Automated determination of urine and cerebrospinal fluid proteins with Coomassie Brilliant Blue and the Abbott ABA-100. *Clin Biochem* 1980; **13**: 81-83.
141. Marshall T, Williams KM. Total protein determination in urine: elimination of a differential response between the coomassie blue and pyrogallol red protein dye-binding assays. *Clin Chem* 2000; **46**: 392-398.
142. Miller WG. Urine albumin: Recommendations for standardization. *Scand J Clin Lab Invest Suppl* 2008; **241**: 71-72.
143. Miller WG, Bruns DE, Hortin GL *et al.* Current issues in measurement and reporting of urinary albumin excretion. *Clin Chem* 2009; **55**: 24-38.
144. Medicines and Healthcare products Regulatory Agency. MHRA 04086 Point of care devices for the quantitation of microalbuminuria. 2004.
145. Medicines and Healthcare products Regulatory Agency. MHRA 04098. Point of care devices for the detection and semi-quantitation of microalbuminuria. 2004.
146. Parsons M, Newman DJ, Pugia M *et al.* Performance of a reagent strip device for quantitation of the urine albumin: creatinine ratio in a point of care setting. *Clin Nephrol* 1999; **51**: 220-227.
147. Parsons MP, Newman DJ, Newall RG *et al.* Validation of a point-of-care assay for the urinary albumin:creatinine ratio. *Clin Chem* 1999; **45**: 414-417.
148. Graziani MS, Gambaro G, Mantovani L *et al.* Diagnostic accuracy of a reagent strip for assessing urinary albumin excretion in the general population. *Nephrol Dial Transplant* 2009; **24**: 1490-1494.
149. Guy M, Newall R, Borzomato J *et al.* Diagnostic accuracy of the urinary albumin: creatinine ratio determined by the CLINITEK Microalbumin and DCA 2000+ for the rule-out of albuminuria in chronic kidney disease. *Clin Chim Acta* 2009; **399**: 54-58.
150. Waugh JJ, Bell SC, Kilby MD *et al.* Optimal bedside urinalysis for the detection of proteinuria in hypertensive pregnancy: a study of diagnostic accuracy. *BJOG* 2005; **112**: 412-417.
151. Iseki K, Iseki C, Ikemiya Y *et al.* Risk of developing end-stage renal disease in a cohort of mass screening. *Kidney Int* 1996; **49**: 800-805.
152. Kaplan RE, Springate JE, Feld LG. Screening dipstick urinalysis: a time to change. *Pediatrics* 1997; **100**: 919-921.
153. Kitagawa T. Lessons learned from the Japanese nephritis screening study. *Pediatr Nephrol* 1988; **2**: 256-263.
154. Boulware LE, Jaar BG, Tarver-Carr ME *et al.* Screening for proteinuria in US adults: a cost-effectiveness analysis. *JAMA* 2003; **290**: 3101-3114.
155. Bowie L, Smith S, Gochman N. Characteristics of binding between reagent-strip indicators and urinary proteins. *Clin Chem* 1977; **23**: 128-130.
156. Gyure WL. Comparison of several methods for semiquantitative determination of urinary protein. *Clin Chem* 1977; **23**: 876-879.

157. James GP, Bee DE, Fuller JB. Proteinuria: accuracy and precision of laboratory diagnosis by dip-stick analysis. *Clin Chem* 1978; **24**: 1934–1939.
158. Rumley A. Urine dipstick testing: comparison of results obtained by visual reading and with the Bayer CLINITEK 50. *Ann Clin Biochem* 2000; **37** (Pt 2): 220–221.
159. Scotti da Silva-Colombeli A, Falkenberg M. Analytical interferences of drugs in the chemical examination of urinary protein. *Clin Biochem* 2007; **40**: 1074–1076.
160. Ralston SH, Caine N, Richards I *et al.* Screening for proteinuria in a rheumatology clinic: comparison of dipstick testing, 24h urine quantitative protein, and protein/creatinine ratio in random urine samples. *Ann Rheum Dis* 1988; **47**: 759–763.
161. Waugh JJ, Clark TJ, Divakaran TG *et al.* Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. *Obstet Gynecol* 2004; **103**: 769–777.
162. White SL, Yu R, Craig JC *et al.* Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. *Am J Kidney Dis* 2011; **58**: 19–28.
163. Saudan PJ, Brown MA, Farrell T *et al.* Improved methods of assessing proteinuria in hypertensive pregnancy. *Br J Obstet Gynaecol* 1997; **104**: 1159–1164.
164. Beetham R, Cattell WR. Proteinuria: pathophysiology, significance and recommendations for measurement in clinical practice. *Ann Clin Biochem* 1993; **30** (Pt 5): 425–434.
165. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; **33**: 1004–1010.
166. Claudi T, Cooper JG. Comparison of urinary albumin excretion rate in overnight urine and albumin creatinine ratio in spot urine in diabetic patients in general practice. *Scand J Prim Health Care* 2001; **19**: 247–248.
167. Gatling W, Knight C, Mullee MA *et al.* Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. *Diabet Med* 1988; **5**: 343–347.
168. Hutchison AS, O'Reilly DS, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. *Clin Chem* 1988; **34**: 2019–2021.
169. Marshall SM. Screening for microalbuminuria: which measurement? *Diabet Med* 1991; **8**: 706–711.
170. Marshall SM, Alberti KG. Screening for early diabetic nephropathy. *Ann Clin Biochem* 1986; **23** (Pt 2): 195–197.
171. Chitalia VC, Kothari J, Wells EJ *et al.* Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. *Clin Nephrol* 2001; **55**: 436–447.
172. Cote AM, Brown MA, Lam E *et al.* Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. *BMJ* 2008; **336**: 1003–1006.
173. Dyson EH, Will EJ, Davison AM *et al.* Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. *Nephrol Dial Transplant* 1992; **7**: 450–452.
174. Ginsberg JM, Chang BS, Matarese RA *et al.* Use of single voided urine samples to estimate quantitative proteinuria. *N Engl J Med* 1983; **309**: 1543–1546.
175. Leanos-Miranda A, Marquez-Acosta J, Romero-Arauz F *et al.* Protein-creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. *Clin Chem* 2007; **53**: 1623–1628.
176. Lemann J, Jr., Doumas BT. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. *Clin Chem* 1987; **33**: 297–299.
177. Ruggenenti P, Gaspari F, Perna A *et al.* Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 h urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. *BMJ* 1998; **316**: 504–509.
178. Pugliese G, Solini A, Fondelli C *et al.* Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. *Nephrol Dial Transplant* 2011; **26**: 3950–3954.
179. Newman DJ, Puglia MJ, Lott JA *et al.* Urinary protein and albumin excretion corrected by creatinine and specific gravity. *Clin Chim Acta* 2000; **294**: 139–155.
180. Howey JE, Browning MC, Fraser CG. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. *Clin Chem* 1987; **33**: 2034–2038.
181. Carter JL, Tomson CR, Stevens PE *et al.* Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. *Nephrol Dial Transplant* 2006; **21**: 3031–3037.
182. Heathcote KL, Wilson MP, Quest DW *et al.* Prevalence and duration of exercise induced albuminuria in healthy people. *Clin Invest Med* 2009; **32**: E261–265.
183. Leung AK, Wong AH. Proteinuria in children. *Am Fam Physician* 2010; **82**: 645–651.
184. Boger CA, Chen MH, Tin A *et al.* CUBN is a gene locus for albuminuria. *J Am Soc Nephrol* 2011; **22**: 555–570.
185. Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. *Clin Chem* 2005; **51**: 1577–1586.
186. National Institute for Health and Clinical Excellence. NICE clinical guideline 73. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. 2008.
187. Montanes Bermudez R, Gracia Garcia S, Perez Surribas D *et al.* Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. *Nefrologia* 2011; **31**: 331–345.
188. Johnson DW, Jones GR, Mathew TH *et al.* Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. *Med J Aust* 2012; **197**: 224–225.
189. Scottish Intercollegiate Guidelines Network. Guideline 103. Diagnosis and management of chronic kidney disease. 2008.
190. Caring for Australasians with Renal Impairment. <http://www.cari.org.au/guidelines.php>
191. Clarke W, Frost SJ, Kraus E *et al.* Renal function testing. In: Nichols JH (ed) *Evidence-based Practice for Point-of-Care Testing*. National Academy of Clinical Biochemistry, 2006, pp 126–134.
192. Panek R, Lawen T, Kiberd BA. Screening for proteinuria in kidney transplant recipients. *Nephrol Dial Transplant* 2011; **26**: 1385–1387.
193. Incerti J, Zelmannovitz T, Camargo JL *et al.* Evaluation of tests for microalbuminuria screening in patients with diabetes. *Nephrol Dial Transplant* 2005; **20**: 2402–2407.
194. Methven S, MacGregor MS, Traynor JP *et al.* Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. *Nephrol Dial Transplant* 2010; **25**: 2991–2996.
195. Methven S, MacGregor MS, Traynor JP *et al.* Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. *Am J Kidney Dis* 2011; **57**: 21–28.
196. Methven S, Traynor JP, Hair MD *et al.* Stratifying risk in chronic kidney disease: an observational study of UK guidelines for measuring total proteinuria and albuminuria. *QJM* 2011; **104**: 663–670.
197. Nauta FL, Bakker SJ, van Oeveren W *et al.* Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. *Am J Kidney Dis* 2011; **57**: 733–743.
198. Elam TJ. Albumin:creatinine ratio—a flawed measure? The merits of estimated albuminuria reporting. *Nephron Clin Pract* 2011; **118**: c324–330.
199. Comper WD, Osicka TM, Clark M *et al.* Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. *Kidney Int* 2004; **65**: 1850–1855.
200. Comper WD, Osicka TM, Jerums G. High prevalence of immunoreactive intact albumin in urine of diabetic patients. *Am J Kidney Dis* 2003; **41**: 336–342.
201. Magliano DJ, Polkinghorne KR, Barr EL *et al.* HPLC-detected albuminuria predicts mortality. *J Am Soc Nephrol* 2007; **18**: 3171–3176.
202. Osicka TM, Comper WD. Characterization of immunochemically non-reactive urinary albumin. *Clin Chem* 2004; **50**: 2286–2291.
203. Sviridov D, Drake SK, Hortin GL. Reactivity of urinary albumin (microalbumin) assays with fragmented or modified albumin. *Clin Chem* 2008; **54**: 61–68.
204. Sviridov D, Meilinger B, Drake SK *et al.* Coelution of other proteins with albumin during size-exclusion HPLC: Implications for analysis of urinary albumin. *Clin Chem* 2006; **52**: 389–397.
205. Tsioufis C, Mazaraki A, Dimitriadis K *et al.* Microalbuminuria in the paediatric age: current knowledge and emerging questions. *Acta Paediatr* 2011; **100**: 1180–1184.
206. Rademacher ER, Sinaiko AR. Albuminuria in children. *Curr Opin Nephrol Hypertens* 2009; **18**: 246–251.
207. Wrong OM, Norden AG, Feest TG. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. *QJM* 1994; **87**: 473–493.
208. Atkins RC, Briganti EM, Zimmet PZ *et al.* Association between albuminuria and proteinuria in the general population: the AusDiab Study. *Nephrol Dial Transplant* 2003; **18**: 2170–2174.

209. Gosling P. Proteinuria. In: Marshall WJ, Bangert SK (eds). *Clinical Biochemistry: Metabolic and Clinical Aspects*, 2nd Ed. Elsevier, 2008, pp 156–173.
210. Goren MP, Li JT. The Coomassie Brilliant Blue method underestimates drug-induced tubular proteinuria. *Clin Chem* 1986; **32**: 386–388.
211. Weber MH, Verwiebe R. Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. *Eur J Clin Chem Clin Biochem* 1992; **30**: 683–691.
212. Herget-Rosenthal S, Poppen D, Husing J *et al*. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. *Clin Chem* 2004; **50**: 552–558.
213. Ginevri F, Piccotti E, Alinovi R *et al*. Reversible tubular proteinuria precedes microalbuminuria and correlates with the metabolic status in diabetic children. *Pediatr Nephrol* 1993; **7**: 23–26.
214. Tomlinson PA, Smellie JM, Prescod N *et al*. Differential excretion of urinary proteins in children with vesicoureteric reflux and reflux nephropathy. *Pediatr Nephrol* 1994; **8**: 21–25.
215. Bird JM, Owen RG, D'Sa S *et al*. Guidelines for the diagnosis and management of multiple myeloma 2011. *Br J Haematol* 2011; **154**: 32–75.
216. Slack TK, Wilson DM. Normal renal function: CIN and CPAH in healthy donors before and after nephrectomy. *Mayo Clinic Proc* 1976; **51**: 296–300.
217. Rowe JW, Andres R, Tobin JD *et al*. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. *J Gerontol* 1976; **31**: 155–163.
218. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. *Kidney Int* 1984; **26**: 861–868.
219. Halbesma N, Kuiken DS, Brantsma AH *et al*. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. *J Am Soc Nephrol* 2006; **17**: 2582–2590.
220. Imai E, Horio M, Yamagata K *et al*. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. *Hypertens Res* 2008; **31**: 433–441.
221. Matsushita K, Selvin E, Bash LD *et al*. Change in estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol* 2009; **20**: 2617–2624.
222. Kronborg J, Solbu M, Njolstad I *et al*. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. *Nephrol Dial Transplant* 2008; **23**: 2818–2826.
223. Hemmelgarn BR, Zhang J, Manns BJ *et al*. Progression of kidney dysfunction in the community-dwelling elderly. *Kidney Int* 2006; **69**: 2155–2161.
224. Keller C, Katz R, Sarnak MJ *et al*. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. *Nephrol Dial Transplant* 2010; **25**: 119–124.
225. John R, Webb M, Young A *et al*. Unreferred chronic kidney disease: a longitudinal study. *Am J Kidney Dis* 2004; **43**: 825–835.
226. Levey AS, Gassman JJ, Hall PM *et al*. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. *J Am Soc Nephrol* 1991; **1**: 1087–1094.
227. Klahr S, Levey AS, Beck GJ *et al*. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994; **330**: 877–884.
228. Wright JT, Jr., Bakris G, Greene T *et al*. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002; **288**: 2421–2431.
229. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. *Kidney Int* 2006; **69**: 375–382.
230. Jones C, Roderick P, Harris S *et al*. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. *Nephrol Dial Transplant* 2006; **21**: 2133–2143.
231. Levin A, Djurdjev O, Beaulieu M *et al*. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. *Am J Kidney Dis* 2008; **52**: 661–671.
232. Al-Aly Z, Zeringue A, Fu J *et al*. Rate of kidney function decline associates with mortality. *J Am Soc Nephrol* 2010; **21**: 1961–1969.
233. Shlipak MG, Katz R, Kestenbaum B *et al*. Rapid decline of kidney function increases cardiovascular risk in the elderly. *J Am Soc Nephrol* 2009; **20**: 2625–2630.
234. Cheng TY, Wen SF, Astor BC *et al*. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. *Am J Kidney Dis* 2008; **52**: 1051–1060.
235. Rifkin DE, Shlipak MG, Katz R *et al*. Rapid kidney function decline and mortality risk in older adults. *Arch Intern Med* 2008; **168**: 2212–2218.
236. Appel LJ, Wright JT, Jr., Greene T *et al*. Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med* 2010; **363**: 918–929.
237. Hunsicker LG, Adler S, Caggiola A *et al*. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int* 1997; **51**: 1908–1919.
238. Menon V, Wang X, Sarnak MJ *et al*. Long-term outcomes in nondiabetic chronic kidney disease. *Kidney Int* 2008; **73**: 1310–1315.
239. Adler AI, Stevens RJ, Manley SE *et al*. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; **63**: 225–232.
240. Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. *J Am Soc Nephrol* 2006; **17**: 339–352.
241. Hoefield RA, Kalra PA, Baker PG *et al*. The use of eGFR and ACR to predict decline in renal function in people with diabetes. *Nephrol Dial Transplant* 2011; **26**: 887–892.
242. Rosolowsky ET, Skupien J, Smiles AM *et al*. Risk for ESRD in type 1 diabetes remains high despite renoprotection. *J Am Soc Nephrol* 2011; **22**: 545–553.
243. Hemmelgarn BR, Clement F, Manns BJ *et al*. Overview of the Alberta Kidney Disease Network. *BMC Nephrol* 2009; **10**: 30.
244. Turin TC, Coresh J, Tonelli M *et al*. One-year change in kidney function is associated with an increased mortality risk. *Am J Nephrol* 2012; **36**: 41–49.
245. Turin TC, Coresh J, Tonelli M *et al*. Short-term change in kidney function and risk of end-stage renal disease. *Nephrol Dial Transplant* 2012; **27**: 3835–3843.
246. Schmierer RE, Mann JF, Schumacher H *et al*. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. *J Am Soc Nephrol* 2011; **22**: 1353–1364.
247. Li L, Astor BC, Lewis J *et al*. Longitudinal Progression Trajectory of GFR Among Patients With CKD. *Am J Kidney Dis* 2012; **59**: 504–512.
248. O'Hare AM, Batten A, Burrows NR *et al*. Trajectories of Kidney Function Decline in the 2 Years Before Initiation of Long-term Dialysis. *Am J Kidney Dis* 2012; **59**: 513–522.
249. Leblanc M, Kellum JA, Gibney RT *et al*. Risk factors for acute renal failure: inherent and modifiable risks. *Curr Opin Crit Care* 2005; **11**: 533–536.
250. Naughton CA. Drug-induced nephrotoxicity. *Am Fam Physician* 2008; **78**: 743–750.
251. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. *Crit Care Med* 2008; **36**: S216–223.
252. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. *Circulation* 2010; **122**: 2451–2455.
253. Black C, Sharma P, Scotland G *et al*. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. *Health Technol Assess* 2010; **14**: 1–184.
254. Bang H, Mazumdar M, Newman G *et al*. Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. *Nephrol Dial Transplant* 2009; **24**: 2452–2457.
255. Johnson ES, Smith DH, Thorp ML *et al*. Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. *BMC Nephrol* 2011; **12**: 17.
256. Wakai K, Kawamura T, Endoh M *et al*. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. *Nephrol Dial Transplant* 2006; **21**: 2800–2808.
257. Keane WF, Zhang Z, Lyle PA *et al*. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. *Clin J Am Soc Nephrol* 2006; **1**: 761–767.
258. Fine EJ, Blaufox MD. Prediction rule for renal artery stenosis. *Ann Intern Med* 1999; **131**: 227–228.
259. Kshirsagar AV, Bang H, Bombardieri AS *et al*. A simple algorithm to predict incident kidney disease. *Arch Intern Med* 2008; **168**: 2466–2473.
260. Tangri N, Stevens LA, Griffith J *et al*. A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011; **305**: 1553–1559.
261. Halbesma N, Jansen DF, Heymans MW *et al*. Development and validation of a general population renal risk score. *Clin J Am Soc Nephrol* 2011; **6**: 1731–1738.
262. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis* 2012; **60**: 850–886.

263. Mittalhenkle A, Stehman-Breen CO, Shlipak MG *et al.* Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. *Clin J Am Soc Nephrol* 2008; **3**: 450–456.
264. Uchino S, Kellum JA, Bellomo R *et al.* Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 2005; **294**: 813–818.
265. Hoste EA, Lameire NH, Vanholder RC *et al.* Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. *J Am Soc Nephrol* 2003; **14**: 1022–1030.
266. McCullough PA, Wolyn R, Rocher LL *et al.* Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med* 1997; **103**: 368–375.
267. Mehran R, Aymong ED, Nikolsky E *et al.* A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004; **44**: 1393–1399.
268. Mehta RH, Grab JD, O'Brien SM *et al.* Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. *Circulation* 2006; **114**: 2208–2216.
269. Thakar CV, Worley S, Arrigain S *et al.* Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. *Kidney Int* 2005; **67**: 1112–1119.
270. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. *Clin J Am Soc Nephrol* 2008; **3**: 844–861.
271. Yegenaga I, Hoste E, Van Biesen W *et al.* Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. *Am J Kidney Dis* 2004; **43**: 817–824.
272. Parfrey PS, Griffiths SM, Barrett BJ *et al.* Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. *N Engl J Med* 1989; **320**: 143–149.
273. Browner WS, Li J, Mangano DT. In-hospital and long-term mortality in male veterans following noncardiac surgery. The Study of Perioperative Ischemia Research Group. *JAMA* 1992; **268**: 228–232.
274. Hou SH, Bushinsky DA, Wish JB *et al.* Hospital-acquired renal insufficiency: a prospective study. *Am J Med* 1983; **74**: 243–248.
275. Singh P, Rifkin DE, Blantz RC. Chronic kidney disease: an inherent risk factor for acute kidney injury? *Clin J Am Soc Nephrol* 2010; **5**: 1690–1695.
276. Lafrance JP, Djurdjev O, Levin A. Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. *Nephrol Dial Transplant* 2010; **25**: 2203–2209.
277. Chapin E, Zhan M, Hsu VD *et al.* Adverse safety events in chronic kidney disease: the frequency of “multiple hits”. *Clin J Am Soc Nephrol* 2010; **5**: 95–101.
278. Chertow GM, Christiansen CL, Cleary PD *et al.* Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. *Arch Intern Med* 1995; **155**: 1505–1511.
279. Chertow GM, Soroko SH, Paganini EP *et al.* Mortality after acute renal failure: models for prognostic stratification and risk adjustment. *Kidney Int* 2006; **70**: 1120–1126.
280. Mehta RL, Pascual MT, Gruta CG *et al.* Refining predictive models in critically ill patients with acute renal failure. *J Am Soc Nephrol* 2002; **13**: 1350–1357.
281. Paganini EP, Larive B, Kanagasundaram NS. Severity scores and outcomes with acute renal failure in the ICU setting. *Contrib Nephrol* 2001; 181–195.
282. Uchino S, Bellomo R, Morimatsu H *et al.* External validation of severity scoring systems for acute renal failure using a multinational database. *Crit Care Med* 2005; **33**: 1961–1967.
283. Waikar SS, Curhan GC, Wald R *et al.* Declining mortality in patients with acute renal failure, 1988 to 2002. *J Am Soc Nephrol* 2006; **17**: 1143–1150.
284. Khosla N, Soroko SB, Chertow GM *et al.* Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. *Clin J Am Soc Nephrol* 2009; **4**: 1914–1919.
285. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. *Cochrane Database Syst Rev* 2009; CD001892.
286. Fouque D, Laville M, Boissel JP *et al.* Controlled low protein diets in chronic renal insufficiency: meta-analysis. *BMJ* 1992; **304**: 216–220.
287. Kasiske BL, Lakatua JD, Ma JZ *et al.* A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. *Am J Kidney Dis* 1998; **31**: 954–961.
288. Pedrini MT, Levey AS, Lau J *et al.* The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. *Ann Intern Med* 1996; **124**: 627–632.
289. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. *Cochrane Database Syst Rev* 2009; CD002181.
290. Menon V, Kopple JD, Wang X *et al.* Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. *Am J Kidney Dis* 2009; **53**: 208–217.
291. Knight EL, Stampfer MJ, Hankinson SE *et al.* The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. *Ann Intern Med* 2003; **138**: 460–467.
292. Chaturvedi S, Jones C. Protein restriction for children with chronic renal failure. *Cochrane Database Syst Rev* 2007; CD006863.
293. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and chronic kidney disease: 2012 Update. *Am J Kidney Dis* 2012; **60**: 850–886.
294. Patel A, MacMahon S, Chalmers J *et al.* Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; **358**: 2560–2572.
295. Ismail-Beigi F, Craven T, Banerji MA *et al.* Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010; **376**: 419–430.
296. Duckworth W, Abraira C, Moritz T *et al.* Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; **360**: 129–139.
297. Nathan DM, Zinman B, Cleary PA *et al.* Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). *Arch Intern Med* 2009; **169**: 1307–1316.
298. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; **352**: 837–853.
299. Ichikawa H, Nagake Y, Takahashi M *et al.* What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? *Nihon Jinzo Gakkai Shi* 1996; **38**: 305–308.
300. Joy MS, Cefalu WT, Hogan SL *et al.* Long-term glycemic control measurements in diabetic patients receiving hemodialysis. *Am J Kidney Dis* 2002; **39**: 297–307.
301. Nakao T, Matsumoto H, Okada T *et al.* Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. *Intern Med* 1998; **37**: 826–830.
302. Ng JM, Cooke M, Bhandari S *et al.* The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. *Diabetes Care* 2010; **33**: 2310–2313.
303. Shima K, Chujo K, Yamada M *et al.* Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. *Ann Clin Biochem* 2012; **49**: 68–74.
304. Vos FE, Schollum JB, Coulter CV *et al.* Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. *Nephrology (Carlton)* 2012; **17**: 182–188.
305. American Diabetes Association. Executive summary: Standards of medical care in diabetes—2012. *Diabetes Care* 2012; **35** (Suppl 1): S4–S10.
306. Jones-Burton C, Mishra SI, Fink JC *et al.* An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. *Am J Nephrol* 2006; **26**: 268–275.
307. Swift PA, Markandu ND, Sagnella GA *et al.* Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. *Hypertension* 2005; **46**: 308–312.
308. Hoffmann IS, Cubeddu LX. Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. *J Hum Hypertens* 2007; **21**: 438–444.
309. Bellizzi V, Di Iorio BR, De Nicola L *et al.* Very low protein diet supplemented with ketoanalogues improves blood pressure control in chronic kidney disease. *Kidney Int* 2007; **71**: 245–251.
310. Slagman MC, Waanders F, Hemmelder MH *et al.* Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. *BMJ* 2011; **343**: d4366.
311. Bellomo G, Venanzi S, Verdura C *et al.* Association of uric acid with change in kidney function in healthy normotensive individuals. *Am J Kidney Dis* 2010; **56**: 264–272.
312. Iseki K, Ikemiya Y, Inoue T *et al.* Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. *Am J Kidney Dis* 2004; **44**: 642–650.
313. Mok Y, Lee SJ, Kim MS *et al.* Serum uric acid and chronic kidney disease: the Severance cohort study. *Nephrol Dial Transplant* 2012; **27**: 1831–1835.
314. Wen CP, David Cheng TY, Chan HT *et al.* Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect

- in a large cohort with low cardiovascular risk. *Am J Kidney Dis* 2010; **56**: 273–288.
315. Yamada T, Fukatsu M, Suzuki S *et al*. Elevated serum uric acid predicts chronic kidney disease. *Am J Med Sci* 2011; **342**: 461–466.
316. Goicoechea M, de Vinuesa SG, Verdalles U *et al*. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol* 2010; **5**: 1388–1393.
317. Siu YP, Leung KT, Tong MK *et al*. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. *Am J Kidney Dis* 2006; **47**: 51–59.
318. Kanbay M, Huddam B, Azak A *et al*. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. *Clin J Am Soc Nephrol* 2011; **6**: 1887–1894.
319. Kanbay M, Ozkara A, Selcoki Y *et al*. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. *Int Urol Nephrol* 2007; **39**: 1227–1233.
320. Kao MP, Ang DS, Gandy SJ *et al*. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 1382–1389.
321. Saito J, Matsuzawa Y, Ito H *et al*. The alkalinizer citrate reduces serum uric acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. *Endocr Res* 2010; **35**: 145–154.
322. Malaguarnera M, Vacante M, Russo C *et al*. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. *Expert Opin Pharmacother* 2009; **10**: 737–742.
323. Miao Y, Ottenbros SA, Laverman GD *et al*. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a *post hoc* analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. *Hypertension* 2011; **58**: 2–7.
324. Johansen KL. Exercise and chronic kidney disease: current recommendations. *Sports Med* 2005; **35**: 485–499.
325. Johansen KL, Chertow GM, Ng AV *et al*. Physical activity levels in patients on hemodialysis and healthy sedentary controls. *Kidney Int* 2000; **57**: 2564–2570.
326. Padilla J, Krasnoff J, Da Silva M *et al*. Physical functioning in patients with chronic kidney disease. *J Nephrol* 2008; **21**: 550–559.
327. Beddhu S, Baird BC, Zitterkoph J *et al*. Physical activity and mortality in chronic kidney disease (NHANES III). *Clin J Am Soc Nephrol* 2009; **4**: 1901–1906.
328. Churchill DN, Torrance GW, Taylor DW *et al*. Measurement of quality of life in end-stage renal disease: the time trade-off approach. *Clin Invest Med* 1987; **10**: 14–20.
329. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. *Am J Kidney Dis* 1997; **30**: 204–212.
330. Booth FW, Gordon SE, Carlson CJ *et al*. Waging war on modern chronic diseases: primary prevention through exercise biology. *J Appl Physiol* 2000; **88**: 774–787.
331. Dickinson HO, Mason JM, Nicolson DJ *et al*. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006; **24**: 215–233.
332. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. *JAMA* 2002; **288**: 1622–1631.
333. Daul AE, Schafers RF, Daul K *et al*. Exercise during hemodialysis. *Clin Nephrol* 2004; **61** (Suppl 1): S26–30.
334. Deligiannis A. Cardiac adaptations following exercise training in hemodialysis patients. *Clin Nephrol* 2004; **61** (Suppl 1): S39–45.
335. Liu SH, C. LC, Yeh SH *et al*. Effect of exercise training on hemodialysis. *Journal of the Formosan Medical Association* 2002; **6**: 129–142.
336. Mustata S, Chan C, Lai V *et al*. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. *J Am Soc Nephrol* 2004; **15**: 2713–2718.
337. Ouzouni S, Kouidi E, Sioulis A *et al*. Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. *Clin Rehabil* 2009; **23**: 53–63.
338. Storer TW, Casaburi R, Sawelson S *et al*. Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. *Nephrol Dial Transplant* 2005; **20**: 1429–1437.
339. Vaitkevicius PV, Fleg JL, Engel JH *et al*. Effects of age and aerobic capacity on arterial stiffness in healthy adults. *Circulation* 1993; **88**: 1456–1462.
340. Mustata S, Groeneveld S, Davidson W *et al*. Effects of exercise training on physical impairment, arterial stiffness and health-related quality of life in patients with chronic kidney disease: a pilot study. *Int Urol Nephrol* 2011; **43**: 1133–1141.
341. Szromba C, Thies MA, Ossman SS. Advancing chronic kidney disease care: new imperatives for recognition and intervention. *Nephrol Nurs J* 2002; **29**: 547–559.
342. Chen PY, Huang YC, Kao YH *et al*. Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients. *J Nurs Res* 2010; **18**: 98–107.
343. Tobita I, Suzuki S, Kobayashi T *et al*. A programme to encourage participation of haemodialysis patients in an exercise regimen. *J Ren Care* 2009; **35**: 48–53.
344. van Vilsteren MC, de Greef MH, Huisman RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. *Nephrol Dial Transplant* 2005; **20**: 141–146.
345. Kosmadakis GC, John SG, Clapp EL *et al*. Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. *Nephrol Dial Transplant* 2012; **27**: 997–1004.
346. Hall JE, Crook ED, Jones DW *et al*. Mechanisms of obesity-associated cardiovascular and renal disease. *Am J Med Sci* 2002; **324**: 127–137.
347. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. *Clin J Am Soc Nephrol* 2007; **2**: 550–562.
348. Wang Y, Chen X, Song Y *et al*. Association between obesity and kidney disease: a systematic review and meta-analysis. *Kidney Int* 2008; **73**: 19–33.
349. Hobbs H, Farmer C, Irving J *et al*. Is high body mass index independently associated with diminished glomerular filtration rate? An epidemiological study. *J Ren Care* 2011; **37**: 148–154.
350. Mohsen A, Brown R, Hoefield R *et al*. Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus. *J Nephrol* 2012; **25**: 384–393.
351. Burton JO, Gray LJ, Webb DR *et al*. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. *Nephrol Dial Transplant* 2012; **27**: 1860–1866.
352. Kasiske BL, Napier J. Glomerular sclerosis in patients with massive obesity. *Am J Nephrol* 1985; **5**: 45–50.
353. Hsu CY, McCulloch CE, Iribarren C *et al*. Body mass index and risk for end-stage renal disease. *Ann Intern Med* 2006; **144**: 21–28.
354. Navaneethan SD, Yehner H, Moustarah F *et al*. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 1565–1574.
355. Afshinnia F, Wilt TJ, Duval S *et al*. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrol Dial Transplant* 2010; **25**: 1173–1183.
356. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients—absence of evidence or evidence of absence? *Clin J Am Soc Nephrol* 2008; **3**: 226–236.
357. Jungers P, Massy ZA, Nguyen Khoa T *et al*. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. *Nephrol Dial Transplant* 1997; **12**: 2597–2602.
358. Muntner P, He J, Astor BC *et al*. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. *J Am Soc Nephrol* 2005; **16**: 529–538.
359. Myllymaki J, Syrjanen J, Helin H *et al*. Vascular diseases and their risk factors in IgA nephropathy. *Nephrol Dial Transplant* 2006; **21**: 1876–1882.
360. Shlipak MG, Fried LF, Cushman M *et al*. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. *JAMA* 2005; **293**: 1737–1745.
361. Chase HP, Garg SK, Marshall G *et al*. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. *JAMA* 1991; **265**: 614–617.
362. Gambaro G, Bax G, Fusaro M *et al*. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. *Diabetes Nutr Metab* 2001; **14**: 337–342.
363. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. *Kidney Int* 2011; **80**: 516–523.
364. Sawicki PT, Didjurgeit U, Muhlhauser I *et al*. Smoking is associated with progression of diabetic nephropathy. *Diabetes Care* 1994; **17**: 126–131.

365. Sung RS, Althoen M, Howell TA *et al*. Excess risk of renal allograft loss associated with cigarette smoking. *Transplantation* 2001; **71**: 1752–1757.
366. Inker LA, Coresh J, Levey AS *et al*. Estimated GFR, albuminuria, and complications of chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 2322–2331.
367. Levin A, Bakris GL, Molitch M *et al*. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int* 2007; **71**: 31–38.
368. World Health Organization. *Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia*. de Benoist B, McLean E, Egli I, and Cogswell M (eds), 2008.
369. Beall CM, Goldstein MC. Hemoglobin concentration of pastoral nomads permanently resident at 4,850–5,450 meters in Tibet. *Am J Phys Anthropol* 1987; **73**: 433–438.
370. Cresanta JL, Croft JB, Webber LS *et al*. Racial difference in hemoglobin concentration of young adults. *Prev Med* 1987; **16**: 659–669.
371. Meyers LD, Habicht JP, Johnson CL. Components of the difference in hemoglobin concentrations in blood between black and white women in the United States. *Am J Epidemiol* 1979; **109**: 539–549.
372. Pan WH, Habicht JP. The non-iron-deficiency-related difference in hemoglobin concentration distribution between blacks and whites and between men and women. *Am J Epidemiol* 1991; **134**: 1410–1416.
373. Centers for Disease Control and Prevention. CDC criteria for anemia in children and childbearing-aged women. *MMWR Morb Mortal Wkly Rep* 1989; **38**: 400–404.
374. Levin A, Djurdjev O, Thompson C *et al*. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. *Am J Kidney Dis* 2005; **46**: 799–811.
375. Pfeffer MA, Burdman EA, Chen CY *et al*. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med* 2009; **361**: 2019–2032.
376. Roger SD, McMahon LP, Clarkson A *et al*. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. *J Am Soc Nephrol* 2004; **15**: 148–156.
377. Moranne O, Froissart M, Rossert J *et al*. Timing of onset of CKD-related metabolic complications. *J Am Soc Nephrol* 2009; **20**: 164–171.
378. Vassalotti JA, Uribarri J, Chen SC *et al*. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999–2004. *Am J Kidney Dis* 2008; **51**: S56–68.
379. Stevens LA, Djurdjev O, Cardew S *et al*. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. *J Am Soc Nephrol* 2004; **15**: 770–779.
380. Gutierrez OM, Isakova T, Andress DL *et al*. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. *Kidney Int* 2008; **73**: 956–962.
381. Gutierrez OM, Farwell WR, Kermah D *et al*. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. *Osteoporos Int* 2011; **22**: 1745–1753.
382. National Kidney Foundation. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. *Am J Kidney Dis* 2009; **53**: S1–124.
383. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. *Kidney Int* 2008; **74**: 721–731.
384. Bacchetta J, Boutroy S, Vilayphiou N *et al*. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II–IV chronic kidney disease. *J Bone Miner Res* 2010; **25**: 849–857.
385. Nickolas TL, Stein E, Cohen A *et al*. Bone mass and microarchitecture in CKD patients with fracture. *J Am Soc Nephrol* 2010; **21**: 1371–1380.
386. Nickolas TL, Cremers S, Zhang A *et al*. Discriminants of prevalent fractures in chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 1560–1572.
387. Palmer SC, Hayen A, Macaskill P *et al*. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. *JAMA* 2011; **305**: 1119–1127.
388. Adeney KL, Siscovick DS, Ix JH *et al*. Association of serum phosphate with vascular and valvular calcification in moderate CKD. *J Am Soc Nephrol* 2009; **20**: 381–387.
389. Moe SM, Zidehsarai MP, Chambers MA *et al*. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 257–264.
390. Sigrist MK, Chiarelli G, Lim L *et al*. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. *J Ren Care* 2009; **35** (Suppl 1): 71–78.
391. Lynch KE, Lynch R, Curhan GC *et al*. Prescribed dietary phosphate restriction and survival among hemodialysis patients. *Clin J Am Soc Nephrol* 2011; **6**: 620–629.
392. Navaneethan SD, Palmer SC, Vecchio M *et al*. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. *Cochrane Database Syst Rev* 2011: CD006023.
393. Mehrotra R, Kermah D, Budoff M *et al*. Hypovitaminosis D in chronic kidney disease. *Clin J Am Soc Nephrol* 2008; **3**: 1144–1151.
394. Navaneethan SD, Schold JD, Arrigain S *et al*. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. *Am J Kidney Dis* 2011; **58**: 536–543.
395. Kandula P, Dobre M, Schold JD *et al*. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Clin J Am Soc Nephrol* 2011; **6**: 50–62.
396. Palmer SC, McGregor DO, Craig JC *et al*. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev* 2009: CD008175.
397. Miller PD. The kidney and bisphosphonates. *Bone* 2011; **49**: 77–81.
398. Torregrosa JV, Ramos AM. [Use of bisphosphonates in chronic kidney disease]. *Nefrologia* 2010; **30**: 288–296.
399. Bhan I, Dubey A, Wolf M. Diagnosis and management of mineral metabolism in CKD. *J Gen Intern Med* 2010; **25**: 710–716.
400. Courtney AE, Leonard N, McCloskey MC *et al*. Bisphosphonate prescribing in chronic kidney disease. *J R Coll Physicians Edinb* 2009; **39**: 4–9.
401. Ayus JC, Krothapalli RK. Effect of bicarbonate administration on cardiac function. *Am J Med* 1989; **87**: 5–6.
402. Bailey JL, Wang X, England BK *et al*. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. *J Clin Invest* 1996; **97**: 1447–1453.
403. Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V *et al*. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. *Kidney Int* 2002; **62**: 2160–2166.
404. Kovsdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. *Nephrol Dial Transplant* 2009; **24**: 1232–1237.
405. Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. *Kidney Int* 1998; **54**: 603–607.
406. Menon V, Tighiouart H, Vaughn NS *et al*. Serum bicarbonate and long-term outcomes in CKD. *Am J Kidney Dis* 2010; **56**: 907–914.
407. Mitch WE, Price SR. Mechanisms activated by kidney disease and the loss of muscle mass. *Am J Kidney Dis* 2001; **38**: 1337–1342.
408. Navaneethan SD, Schold JD, Arrigain S *et al*. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 2395–2402.
409. Raphael KL, Wei G, Baird BC *et al*. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. *Kidney Int* 2011; **79**: 356–362.
410. Shah SN, Abramowitz M, Hostetter TH *et al*. Serum bicarbonate levels and the progression of kidney disease: a cohort study. *Am J Kidney Dis* 2009; **54**: 270–277.
411. Bright R. *Reports of Medical Cases, Selected with a View of Illustrating the Symptoms and Cure of Diseases by a Reference to Morbid Anatomy, Volume 1*. London: Brown & Green. 1827.
412. Osman AA. The value of alkalis in the treatment of chronic nephritis. *Lancet* 1930; **2**: 945–959.
413. Lyon DM, Dunlop DM, Stewart CP. The alkaline treatment of chronic nephritis. *Lancet* 1931; **2**: 1009–1013.
414. Rustom R, Grime JS, Costigan M *et al*. Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients. *Ren Fail* 1998; **20**: 371–382.
415. Mathur RP, Dash SC, Gupta N *et al*. Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease: a prospective randomized single blind controlled trial. *Ren Fail* 2006; **28**: 1–5.
416. de Brito-Ashurst I, Varaganam M, Raftery MJ *et al*. Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol* 2009; **20**: 2075–2084.

417. Phisitkul S, Khanna A, Simoni J *et al*. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. *Kidney Int* 2010; **77**: 617–623.
418. Husted FC, Nolph KD, Maher JF. NaHCO₃ and NaCl tolerance in chronic renal failure. *J Clin Invest* 1975; **56**: 414–419.
419. Husted FC, Nolph KD. NaHCO₃ and NaCl tolerance in chronic renal failure II. *Clin Nephrol* 1977; **7**: 21–25.
420. Hallan SI, Dahl K, Oien CM *et al*. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. *BMJ* 2006; **333**: 1047.
421. McCullough PA, Li S, Jurkovic CT *et al*. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. *Am Heart J* 2008; **156**: 277–283.
422. Anavekar NS, McMurray JJ, Velazquez EJ *et al*. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 2004; **351**: 1285–1295.
423. Shlipak MG, Heidenreich PA, Noguchi H *et al*. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. *Ann Intern Med* 2002; **137**: 555–562.
424. Wright RS, Reeder GS, Herzog CA *et al*. Acute myocardial infarction and renal dysfunction: a high-risk combination. *Ann Intern Med* 2002; **137**: 563–570.
425. Sarnak MJ. Cardiovascular complications in chronic kidney disease. *Am J Kidney Dis* 2003; **41**: 11–17.
426. Hemmelgarn BR, Manns BJ, Lloyd A *et al*. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA* 2010; **303**: 423–429.
427. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B *et al*. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation* 2004; **110**: 32–35.
428. Gerstein HC, Mann JF, Yi Q *et al*. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; **286**: 421–426.
429. Hallan S, Astor B, Romundstad S *et al*. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. *Arch Intern Med* 2007; **167**: 2490–2496.
430. Ibsen H, Wachtell K, Olsen MH *et al*. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. *Kidney Int Suppl* 2004; **92**: S56–58.
431. Menon V, Shlipak MG, Wang X *et al*. Cystatin C as a risk factor for outcomes in chronic kidney disease. *Ann Intern Med* 2007; **147**: 19–27.
432. Peralta CA, Katz R, Sarnak MJ *et al*. Cystatin C identifies chronic kidney disease patients at higher risk for complications. *J Am Soc Nephrol* 2011; **22**: 147–155.
433. Phrommintikul A, Haas SJ, Elsik M *et al*. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet* 2007; **369**: 381–388.
434. Strippoli GF, Tognoni G, Navaneethan SD *et al*. Haemoglobin targets: we were wrong, time to move on. *Lancet* 2007; **369**: 346–350.
435. Eckardt KU, Scherhag A, Macdougall IC *et al*. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. *J Am Soc Nephrol* 2009; **20**: 2651–2660.
436. Kestenbaum B, Sampson JN, Rudser KD *et al*. Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol* 2005; **16**: 520–528.
437. Groothoff JW, Gruppen MP, Offringa M *et al*. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. *Kidney Int* 2002; **61**: 621–629.
438. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. *N Engl J Med* 2004; **350**: 2654–2662.
439. Oh J, Wunsch R, Turzer M *et al*. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation* 2002; **106**: 100–105.
440. Parekh RS, Carroll CE, Wolfe RA *et al*. Cardiovascular mortality in children and young adults with end-stage kidney disease. *J Pediatr* 2002; **141**: 191–197.
441. Kavey RE, Allada V, Daniels SR *et al*. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2006; **114**: 2710–2738.
442. Wilson AC, Schneider MF, Cox C *et al*. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 2759–2765.
443. Litwin M, Wuhl E, Jourdan C *et al*. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. *J Am Soc Nephrol* 2005; **16**: 1494–1500.
444. Mitsnefes MM, Kimball TR, Kartal J *et al*. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. *J Am Soc Nephrol* 2005; **16**: 2796–2803.
445. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. *J Am Soc Nephrol* 2012; **23**: 578–585.
446. Shroff R, Weaver DJ, Jr., Mitsnefes MM. Cardiovascular complications in children with chronic kidney disease. *Nat Rev Nephrol* 2011; **7**: 642–649.
447. Halimi JM, Giraudeau B, Vol S *et al*. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. *Kidney Int* 2000; **58**: 1285–1292.
448. Boyce ML, Robergs RA, Avasthi PS *et al*. Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension, and renal function. *Am J Kidney Dis* 1997; **30**: 180–192.
449. Baigent C, Landray MJ, Reith C *et al*. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011; **377**: 2181–2192.
450. Jardine MJ, Ninomiya T, Perkovic V *et al*. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. *J Am Coll Cardiol* 2010; **56**: 956–965.
451. Angiolillo DJ, Bernardo E, Capodanno D *et al*. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. *J Am Coll Cardiol* 2010; **55**: 1139–1146.
452. Best PJ, Steinhubl SR, Berger PB *et al*. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. *Am Heart J* 2008; **155**: 687–693.
453. Graham I, Atar D, Borch-Johnsen K *et al*. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil* 2007; **14** (Suppl 2): E1–40.
454. Hippisley-Cox J, Coupland C, Vinogradova Y *et al*. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008; **336**: 1475–1482.
455. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart* 2005; **91** (Suppl 5): v1–52.
456. Wu Y, Liu X, Li X *et al*. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. *Circulation* 2006; **114**: 2217–2225.
457. Liao SY, Izhham MI, Hassali MA *et al*. A literature review of the cardiovascular risk-assessment tools: applicability among Asian population. *Heart Asia* 2010; **2**: 15–18.
458. Nakayama M, Sato T, Sato H *et al*. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. *Clin Exp Nephrol* 2010; **14**: 333–339.
459. Irie F, Iso H, Sairenchi T *et al*. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int* 2006; **69**: 1264–1271.
460. Yang JG, Li J, Lu C *et al*. Chronic kidney disease, all-cause mortality and cardiovascular mortality among Chinese patients with established cardiovascular disease. *J Atheroscler Thromb* 2010; **17**: 395–401.
461. Zhang L, Zuo L, Wang F *et al*. Cardiovascular disease in early stages of chronic kidney disease in a Chinese population. *J Am Soc Nephrol* 2006; **17**: 2617–2621.
462. Banerjee D, Chitalia N, Raja R *et al*. Metabolic syndrome in chronic kidney disease and renal transplant patients in North India. *Int Urol Nephrol* 2012; **44**: 937–943.
463. Di Angelantonio E, Chowdhury R, Sarwar N *et al*. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. *BMJ* 2010; **341**: c4986.
464. Parikh NI, Hwang SJ, Larson MG *et al*. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). *Am J Cardiol* 2008; **102**: 47–53.

465. Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. *J Pediatr Pharmacol Ther* 2010; **15**: 160–172.
466. McAlister FA, Ezekowitz J, Tonelli M *et al*. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. *Circulation* 2004; **109**: 1004–1009.
467. Smith GL, Lichtman JH, Bracken MB *et al*. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. *J Am Coll Cardiol* 2006; **47**: 1987–1996.
468. Hillege HL, Nitsch D, Pfeffer MA *et al*. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation* 2006; **113**: 671–678.
469. Shlipak MG, Smith GL, Rathore SS *et al*. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. *J Am Soc Nephrol* 2004; **15**: 2195–2203.
470. Smith GL, Shlipak MG, Havranek EP *et al*. Race and renal impairment in heart failure: mortality in blacks versus whites. *Circulation* 2005; **111**: 1270–1277.
471. Anand IS, Bishu K, Rector TS *et al*. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. *Circulation* 2009; **120**: 1577–1584.
472. Ezekowitz J, McAlister FA, Humphries KH *et al*. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. *J Am Coll Cardiol* 2004; **44**: 1587–1592.
473. Gottlieb SS, Abraham W, Butler J *et al*. The prognostic importance of different definitions of worsening renal function in congestive heart failure. *J Card Fail* 2002; **8**: 136–141.
474. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. *J Am Soc Nephrol* 2001; **12**: 1079–1084.
475. Levin A, Singer J, Thompson CR *et al*. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. *Am J Kidney Dis* 1996; **27**: 347–354.
476. Ha SK, Park HS, Kim SJ *et al*. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. *J Korean Med Sci* 1998; **13**: 488–494.
477. Parfrey PS, Foley RN, Harnett JD *et al*. Outcome and risk factors for left ventricular disorders in chronic uraemia. *Nephrol Dial Transplant* 1996; **11**: 1277–1285.
478. Cerasola G, Nardi E, Palermo A *et al*. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. *J Nephrol* 2011; **24**: 1–10.
479. Ahmed A, Rich MW, Sanders PW *et al*. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. *Am J Cardiol* 2007; **99**: 393–398.
480. Lazzeri C, Valente S, Tarquini R *et al*. Cardiorenal syndrome caused by heart failure with preserved ejection fraction. *Int J Nephrol* 2011; 634903.
481. Levin A, Thompson CR, Ethier J *et al*. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. *Am J Kidney Dis* 1999; **34**: 125–134.
482. Go AS, Yang J, Ackerson LM *et al*. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. *Circulation* 2006; **113**: 2713–2723.
483. Shlipak MG, Katz R, Kestenbaum B *et al*. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. *Atherosclerosis* 2009; **204**: 298–303.
484. Balamuthusamy S, Srinivasan L, Verma M *et al*. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. *Am Heart J* 2008; **155**: 791–805.
485. Lewis EJ, Hunsicker LG, Clarke WR *et al*. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; **345**: 851–860.
486. Erdmann E, Lechat P, Verkenne P *et al*. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Eur J Heart Fail* 2001; **3**: 469–479.
487. Wali RK, Iyengar M, Beck GJ *et al*. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. *Circ Heart Fail* 2011; **4**: 18–26.
488. Pitt B, Zannad F, Remme WJ *et al*. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999; **341**: 709–717.
489. Juurlink DN, Mamdani MM, Lee DS *et al*. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med* 2004; **351**: 543–551.
490. Abdel-Qadir HM, Chugh S, Lee DS. Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. *Int J Nephrol* 2011; 351672.
491. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *N Engl J Med* 1998; **339**: 321–328.
492. Wiley CL, Switzer SP, Berg RL *et al*. Association of B-type natriuretic peptide levels with estimated glomerular filtration rate and congestive heart failure. *Clin Med Res* 2010; **8**: 7–12.
493. Madsen LH, Ladefoged S, Corell P *et al*. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. *Kidney Int* 2007; **71**: 548–554.
494. Gustafsson F, Steensgaard-Hansen F, Badskaer J *et al*. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. *J Card Fail* 2005; **11**: S15–20.
495. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. *Rev Cardiovasc Med* 2003; **4**: 72–80.
496. Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. *Clin Cornerstone* 2005; **7** (Suppl 1): S7–17.
497. Wright SP, Doughty RN, Pearl A *et al*. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. *J Am Coll Cardiol* 2003; **42**: 1793–1800.
498. Yamamoto K, Burnett JC, Jr., Jougasaki M *et al*. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. *Hypertension* 1996; **28**: 988–994.
499. Burnett JC, Jr., Kao PC, Hu DC *et al*. Atrial natriuretic peptide elevation in congestive heart failure in the human. *Science* 1986; **231**: 1145–1147.
500. Mueller C, Laule-Kilian K, Scholer A *et al*. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. *Kidney Int* 2005; **67**: 278–284.
501. Vickery S, Price CP, John RI *et al*. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. *Am J Kidney Dis* 2005; **46**: 610–620.
502. Ishibe S, Peixoto AJ. Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice. *Semin Dial* 2004; **17**: 37–43.
503. Takahashi M, Nagake Y, Ichikawa H *et al*. Plasma concentrations of natriuretic peptides in patients on hemodialysis. *Res Commun Mol Pathol Pharmacol* 1996; **92**: 19–30.
504. Tagore R, Ling LH, Yang H *et al*. Natriuretic peptides in chronic kidney disease. *Clin J Am Soc Nephrol* 2008; **3**: 1644–1651.
505. Takami Y, Horio T, Iwashima Y *et al*. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. *Am J Kidney Dis* 2004; **44**: 420–428.
506. Zoccali C, Mallamaci F, Benedetto FA *et al*. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. *J Am Soc Nephrol* 2001; **12**: 1508–1515.
507. Suresh M, Farrington K. Natriuretic peptides and the dialysis patient. *Semin Dial* 2005; **18**: 409–419.
508. Kistorp C, Raymond I, Pedersen F *et al*. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA* 2005; **293**: 1609–1616.
509. Bettencourt P, Azevedo A, Pimenta J *et al*. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation* 2004; **110**: 2168–2174.
510. Gardner RS, Ozalp F, Murday AJ *et al*. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. *Eur Heart J* 2003; **24**: 1735–1743.
511. Kragelund CB, Gronning BA, Kober L *et al*. [Prognostic value of N-terminal pro-BNP-type natriuretic peptide in patients with stable coronary heart disease—secondary publication]. *Ugeskr Laeger* 2006; **168**: 697–700.
512. Omland T, Persson A, Ng L *et al*. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. *Circulation* 2002; **106**: 2913–2918.
513. Olsen MH, Wachtell K, Tuxen C *et al*. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. *J Hypertens* 2004; **22**: 1597–1604.
514. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. *Heart* 2003; **89**: 875–878.

515. Auerbach SR, Richmond ME, Lamour JM *et al.* BNP levels predict outcome in pediatric heart failure patients: *post hoc* analysis of the Pediatric Carvedilol Trial. *Circ Heart Fail* 2010; **3**: 606–611.
516. Barret BJ, Culleton B. Reducing the burden of cardiovascular disease in patients on dialysis. *Dial Transplant* 2002; **31**: 155–163.
517. Beciani M, Tedesco A, Violante A *et al.* Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. *Nephrol Dial Transplant* 2003; **18**: 942–946.
518. Apple FS, Wu AH. Myocardial infarction redefined: role of cardiac troponin testing. *Clin Chem* 2001; **47**: 377–379.
519. McLaurin MD, Apple FS, Voss EM *et al.* Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. *Clin Chem* 1997; **43**: 976–982.
520. Musso P, Cox I, Vidano E *et al.* Cardiac troponin elevations in chronic renal failure: prevalence and clinical significance. *Clin Biochem* 1999; **32**: 125–130.
521. Alpert JS, Thygesen K, Antman E *et al.* Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000; **36**: 959–969.
522. Collinson PO, Boa FG, Gaze DC. Measurement of cardiac troponins. *Ann Clin Biochem* 2001; **38**: 423–449.
523. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term anti-thrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. *J Am Coll Cardiol* 1997; **29**: 43–48.
524. Rabbani LE. Acute coronary syndromes—beyond myocyte necrosis. *N Engl J Med* 2001; **345**: 1057–1059.
525. Tun A, Khan IA, Win MT *et al.* Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. *Cardiology* 1998; **90**: 280–285.
526. Wood GN, Keevil B, Gupta J *et al.* Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. *Nephrol Dial Transplant* 2003; **18**: 1610–1615.
527. Abbas NA, John RI, Webb MC *et al.* Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem* 2005; **51**: 2059–2066.
528. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. *Endocrinology* 1993; **132**: 1961–1970.
529. deFilippi C, Wasserman S, Rosanio S *et al.* Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA* 2003; **290**: 353–359.
530. Hayashi T, Obi Y, Kimura T *et al.* Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy. *Nephrol Dial Transplant* 2008; **23**: 2936–2942.
531. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. *Chest* 2004; **125**: 1877–1884.
532. Apple FS, Murakami MM, Pearce LA *et al.* Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem* 2004; **50**: 2279–2285.
533. De Zoysa JR. Cardiac troponins and renal disease. *Nephrology (Carlton)* 2004; **9**: 83–88.
534. Deegan PB, Lafferty ME, Blumsohn A *et al.* Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. *Kidney Int* 2001; **60**: 2399–2405.
535. Dierkes J, Domrose U, Westphal S *et al.* Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation* 2000; **102**: 1964–1969.
536. Fehr T, Knoflach A, Ammann P *et al.* Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin Nephrol* 2003; **59**: 35–39.
537. Francis GS, Tang WH. Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. *Prog Cardiovasc Dis* 2004; **47**: 196–206.
538. Freda BJ, Tang WH, Van Lente F *et al.* Cardiac troponins in renal insufficiency: review and clinical implications. *J Am Coll Cardiol* 2002; **40**: 2065–2071.
539. Iliou MC, Fumeron C, Benoit MO *et al.* Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. *Nephrol Dial Transplant* 2001; **16**: 1452–1458.
540. Lamb EJ, Webb MC, Abbas NA. The significance of serum troponin T in patients with kidney disease: a review of the literature. *Ann Clin Biochem* 2004; **41**: 1–9.
541. Lowbeer C, Ottosson-Seeberger A, Gustafsson SA *et al.* Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. *Nephrol Dial Transplant* 1999; **14**: 1948–1955.
542. Mallamaci F, Zoccali C, Parlongo S *et al.* Troponin I is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* 2002; **40**: 68–75.
543. Needham DM, Shufelt KA, Tomlinson G *et al.* Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. *Can J Cardiol* 2004; **20**: 1212–1218.
544. Ooi DS, Zimmerman D, Graham J *et al.* Cardiac troponin T predicts long-term outcomes in hemodialysis patients. *Clin Chem* 2001; **47**: 412–417.
545. Roberts MA, Fernando D, Macmillan N *et al.* Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. *Clin Nephrol* 2004; **61**: 40–46.
546. Collinson PO, Hadcocks L, Foo Y *et al.* Cardiac troponins in patients with renal dysfunction. *Ann Clin Biochem* 1998; **35** (Pt 3): 380–386.
547. Roppolo LP, Fitzgerald R, Dillow J *et al.* A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. *J Am Coll Cardiol* 1999; **34**: 448–454.
548. de Lemos JA, Drazner MH, Omland T *et al.* Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA* 2010; **304**: 2503–2512.
549. Haller C, Zehelein J, Remppis A *et al.* Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. *Clin Chem* 1998; **44**: 930–938.
550. Abaci A, Ekici E, Oguzhan A *et al.* Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. *Clin Cardiol* 2004; **27**: 704–709.
551. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. *Clin Chem* 1998; **44**: 1410–1416.
552. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. *J Am Soc Nephrol* 1999; **10**: 1606–1615.
553. Roberts MA, Hedley AJ, Ierino FL. Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application. *Nephrology (Carlton)* 2011; **16**: 251–260.
554. Hirsch R, Landt Y, Porter S *et al.* Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury. *J Pediatr* 1997; **130**: 872–877.
555. Liesemer K, Casper TC, Korgenski K *et al.* Use and misuse of serum troponin assays in pediatric practice. *Am J Cardiol* 2012; **110**: 284–289.
556. Lentine KL, Hurst FP, Jindal RM *et al.* Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. *Am J Kidney Dis* 2010; **55**: 152–167.
557. McIntyre CW, Odudu A, Eldehni MT. Cardiac assessment in chronic kidney disease. *Curr Opin Nephrol Hypertens* 2009; **18**: 501–506.
558. Bennett WM, Kloster F, Rosch J *et al.* Natural history of asymptomatic coronary arteriographic lesions in diabetic patients with end-stage renal disease. *Am J Med* 1978; **65**: 779–784.
559. Braun WE, Phillips DF, Vidt DG *et al.* Coronary artery disease in 100 diabetics with end-stage renal failure. *Transplant Proc* 1984; **16**: 603–607.
560. Lorber MI, Van Buren CT, Flechner SM *et al.* Pretransplant coronary arteriography for diabetic renal transplant recipients. *Transplant Proc* 1987; **19**: 1539–1541.
561. Manske CL, Wilson RF, Wang Y *et al.* Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. *Arch Intern Med* 1992; **152**: 2450–2455.
562. Weinrauch L, D'Elia JA, Healy RW *et al.* Asymptomatic coronary artery disease: angiographic assessment of diabetics evaluated for renal transplantation. *Circulation* 1978; **58**: 1184–1190.
563. Klocke FJ, Baird MG, Lorell BH *et al.* ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). *J Am Coll Cardiol* 2003; **42**: 1318–1333.
564. Dahan M, Viron BM, Faraggi M *et al.* Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. *Kidney Int* 1998; **54**: 255–262.
565. Koistinen MJ, Huikuri HV, Pirttiäho H *et al.* Evaluation of exercise electrocardiography and thallium tomographic imaging in detecting asymptomatic coronary artery disease in diabetic patients. *Br Heart J* 1990; **63**: 7–11.

566. Marwick TH, Steinmuller DR, Underwood DA *et al.* Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. *Transplantation* 1990; **49**: 100–103.
567. Schmidt A, Stefanelli T, Schuster E *et al.* Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. *Am J Kidney Dis* 2001; **37**: 56–63.
568. Morrow CE, Schwartz JS, Sutherland DE *et al.* Predictive value of thallium stress testing for coronary and cardiovascular events in uremic diabetic patients before renal transplantation. *Am J Surg* 1983; **146**: 331–335.
569. Patel AD, Abo-Auda WS, Davis JM *et al.* Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. *Am J Cardiol* 2003; **92**: 146–151.
570. Rabbat CG, Treleaven DJ, Russell JD *et al.* Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. *J Am Soc Nephrol* 2003; **14**: 431–439.
571. Wong CF, Little MA, Vinjamuri S *et al.* Technetium myocardial perfusion scanning in prerenal transplant evaluation in the United Kingdom. *Transplant Proc* 2008; **40**: 1324–1328.
572. De Lima JJ, Sabbaga E, Vieira ML *et al.* Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. *Hypertension* 2003; **42**: 263–268.
573. Hatta T, Nishimura S, Nishimura T. Prognostic risk stratification of myocardial ischaemia evaluated by gated myocardial perfusion SPECT in patients with chronic kidney disease. *Eur J Nucl Med Mol Imaging* 2009; **36**: 1835–1841.
574. Kusuoka H, Nishimura S, Yamashina A *et al.* Surveillance study for creating the national clinical database related to ECG-gated myocardial perfusion SPECT of ischemic heart disease: J-ACCESS study design. *Ann Nucl Med* 2006; **20**: 195–202.
575. Momose M, Babazono T, Kondo C *et al.* Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. *Eur J Nucl Med Mol Imaging* 2009; **36**: 1315–1321.
576. Nakajima K, Nishimura T. Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated SPECT with ^{99m}Tc-tetrofosmin: a multicentre study involving 106 hospitals. *Eur J Nucl Med Mol Imaging* 2006; **33**: 127–133.
577. Nekolla SG, Reder S, Saraste A *et al.* Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. *Circulation* 2009; **119**: 2333–2342.
578. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; **69**: 89–95.
579. Ix JH, Criqui MH. Epidemiology and diagnosis of peripheral arterial disease in patients with chronic kidney disease. *Adv Chronic Kidney Dis* 2008; **15**: 378–383.
580. Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. *Nat Rev Cardiol* 2011; **8**: 405–418.
581. Bello AK, Hemmelgarn B, Lloyd A *et al.* Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. *Clin J Am Soc Nephrol* 2011; **6**: 1418–1426.
582. de Vinuesa SG, Ortega M, Martinez P *et al.* Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. *Kidney Int Suppl* 2005; **93**: S44–47.
583. Lash JP, Go AS, Appel LJ *et al.* Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol* 2009; **4**: 1302–1311.
584. Liew YP, Bartholomew JR, Demirjian S *et al.* Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. *Clin J Am Soc Nephrol* 2008; **3**: 1084–1089.
585. O'Hare AM, Glidden DV, Fox CS *et al.* High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999–2000. *Circulation* 2004; **109**: 320–323.
586. O'Hare AM, Newman AB, Katz R *et al.* Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. *Arch Intern Med* 2005; **165**: 2666–2670.
587. O'Hare AM, Vittinghoff E, Hsia J *et al.* Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). *J Am Soc Nephrol* 2004; **15**: 1046–1051.
588. Wattanakit K, Folsom AR, Criqui MH *et al.* Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA). *Atherosclerosis* 2008; **201**: 212–216.
589. Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. *Diabetes Care* 2008; **31**: 1331–1336.
590. Fuster V, Ryden LE, Cannon DS *et al.* ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006; **114**: e257–354.
591. Abbas AE, Goodman LM, Timmis R *et al.* Predictors of poor outcome in female patients undergoing endovascular intervention. *J Interv Cardiol* 2010; **23**: 401–410.
592. O'Hare AM, Bertenthal D, Sidawy AN *et al.* Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. *Clin J Am Soc Nephrol* 2006; **1**: 297–304.
593. *Goodman and Gilman's Pharmacological Basis of Therapeutics*, 12th Edn. Brunton LL, Chabner BA, Knollman BA (eds). McGraw-Hill: New York, 2011.
594. *Martindale: The Complete Drug Reference*, 37th Edn. Sweetman SC (ed). Royal Pharmaceutical Society, London, 2011.
595. Gokmen MR, Lord GM. Aristolochic acid nephropathy. *BMJ* 2012; **344**: e4000.
596. Su T, Zhang L, Li X *et al.* Regular use of nephrotoxic medications is an independent risk factor for chronic kidney disease—results from a Chinese population study. *Nephrol Dial Transplant* 2011; **26**: 1916–1923.
597. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 38: Bipolar Disorder. 2006.
598. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. *Diabetes Care* 2011; **34**: 1431–1437.
599. Rachmani R, Slavachevski I, Levi Z *et al.* Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. *Eur J Intern Med* 2002; **13**: 428.
600. Salpeter S, Greyber E, Pasternak G *et al.* Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2010; CD002967.
601. Fellstrom BC, Jardine AG, Schmieder RE *et al.* Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med* 2009; **360**: 1395–1407.
602. Ginsberg HN, Elam MB, Lovato LC *et al.* Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010; **362**: 1563–1574.
603. Keech A, Simes RJ, Barter P *et al.* Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005; **366**: 1849–1861.
604. Wanner C, Krane V, Marz W *et al.* Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005; **353**: 238–248.
605. Limdi NA, Beasley TM, Baird MF *et al.* Kidney function influences warfarin responsiveness and hemorrhagic complications. *J Am Soc Nephrol* 2009; **20**: 912–921.
606. Wahba IM, Olyaei AJ, Rozansky D *et al.* Handling of drugs in children with abnormal renal function, in *Pediatric Nephrology*, eds. Avner ED, Harmon WE, Niaudet P, Yoshikawa, N. Springer-Verlag: 2009, pp 1693–1711.
607. Blowey DL. Chapter 64: Drug Use and Dosage in Renal Failure, in *Comprehensive Pediatric Nephrology*, eds. Geary DF, Schaefer F. Mosby Elsevier: Philadelphia, 2008, pp 991–1002.
608. *Drug prescribing in renal failure*. <http://www.kdp-baptist.louisville.edu/renalbook/>.
609. Goldfarb S, McCullough PA, McDermott J *et al.* Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. *Mayo Clin Proc* 2009; **84**: 170–179.
610. American College Radiology Guidelines. *Manual on Contrast Media Version 8*. [http://www.acr.org/~media/ACR/Documents/PDF/Quality Safety/Resources/Contrast%20Manual/Contrast%20Nephrotoxicity.pdf](http://www.acr.org/~media/ACR/Documents/PDF/Quality%20Safety/Resources/Contrast%20Manual/Contrast%20Nephrotoxicity.pdf). Accessed October 12, 2012.
611. European Society for Urological Radiology (ESUR). <http://www.esur.org/Contrast-media.51.0.html>, Accessed October 9, 2012.

612. Heinrich MC, Haberle L, Muller V *et al*. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. *Radiology* 2009; **250**: 68–86.
613. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. *Clin J Am Soc Nephrol* 2009; **4**: 461–469.
614. Agarwal R, Brunelli SM, Williams K *et al*. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2009; **24**: 856–863.
615. American College Radiology Guidelines. *Manual on Contrast Media Version 8*. <http://www.acr.org/~/media/ACR/Documents/PDF/Quality-Safety/Resources/Contrast%20Manual/Nephrogenic%20Systemic%20Fibrosis.pdf>. Accessed October 12, 2012.
616. Saitoh T, Hayasaka K, Tanaka Y *et al*. Dialyzability of gadodiamide in hemodialysis patients. *Radiat Med* 2006; **24**: 445–451.
617. Meng H, Grosse-Wortmann L. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. *J Cardiovasc Magn Reson* 2012; **14**: 56.
618. Lien YH. Is bowel preparation before colonoscopy a risky business for the kidney? *Nat Clin Pract Nephrol* 2008; **4**: 606–614.
619. Markowitz GS, Perazella MA. Acute phosphate nephropathy. *Kidney Int* 2009; **76**: 1027–1034.
620. Heher EC, Thier SO, Rennek H *et al*. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. *Clin J Am Soc Nephrol* 2008; **3**: 1494–1503.
621. Palmadottir VK, Gudmundsson H, Hardarson S *et al*. Incidence and outcome of acute phosphate nephropathy in Iceland. *PLoS One* 2010; **5**: e13484.
622. Wexner SD, Beck DE, Baron TH *et al*. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). *Gastrointest Endosc* 2006; **63**: 894–909.
623. Brunelli SM. Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **53**: 448–456.
624. Johanson JF, Popp JW, Jr., Cohen LB *et al*. A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing. *Am J Gastroenterol* 2007; **102**: 2238–2246.
625. Foley RN, Guo H, Snyder JJ *et al*. Septicemia in the United States dialysis population, 1991 to 1999. *J Am Soc Nephrol* 2004; **15**: 1038–1045.
626. Hoen B, Paul-Dauphin A, Hestin D *et al*. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol* 1998; **9**: 869–876.
627. Ishani A, Collins AJ, Herzog CA *et al*. Septicemia, access and cardiovascular disease in dialysis patients: the USRD Wave 2 study. *Kidney Int* 2005; **68**: 311–318.
628. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. *Kidney Int* 2000; **58**: 1758–1764.
629. Fried LF, Katz R, Sarnak MJ *et al*. Kidney function as a predictor of noncardiovascular mortality. *J Am Soc Nephrol* 2005; **16**: 3728–3735.
630. Nissen AR, Collins AJ, Hurlay J *et al*. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. *J Am Soc Nephrol* 2001; **12**: 1713–1720.
631. US Renal Data System. *Atlas of Chronic Kidney Disease in the United States*. Bethesda, MD: National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2007.
632. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. *Adv Chronic Kidney Dis* 2006; **13**: 199–204.
633. US Renal Data System. *Atlas of Chronic Kidney Disease in the United States*. Bethesda, MD: National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2010.
634. McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. *J Paediatr Child Health* 1998; **34**: 314–317.
635. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. *J Am Soc Nephrol* 1993; **3**: 1541–1554.
636. Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. *Kidney Int Suppl* 1997; **62**: 579–82.
637. Minnaganti VR, Cunha BA. Infections associated with uremia and dialysis. *Infect Dis Clin North Am* 2001; **15**: 385–406.
638. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. *Infect Dis Clin North Am* 2001; **15**: 813–832.
639. Kausz AT, Guo H, Pereira BJ *et al*. General medical care among patients with chronic kidney disease: opportunities for improving outcomes. *J Am Soc Nephrol* 2005; **16**: 3092–3101.
640. DaRoza G, Loewen A, Djurdjev O *et al*. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. *Am J Kidney Dis* 2003; **42**: 1184–1192.
641. Kausz AT, Gilbertson DT. Overview of vaccination in chronic kidney disease. *Adv Chronic Kidney Dis* 2006; **13**: 209–214.
642. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients: a comparison of two vaccination schedules. *Vaccine* 2005; **23**: 4142–4147.
643. Robinson J. Efficacy of pneumococcal immunization in patients with renal disease—what is the data? *Am J Nephrol* 2004; **24**: 402–409.
644. Gilbertson DT, Unruh M, McBean AM *et al*. Influenza vaccine delivery and effectiveness in end-stage renal disease. *Kidney Int* 2003; **63**: 738–743.
645. Dinits-Pensy M, Forrest GN, Cross AS *et al*. The use of vaccines in adult patients with renal disease. *Am J Kidney Dis* 2005; **46**: 997–1011.
646. Nikoskelainen J, Koskela M, Forsstrom J *et al*. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. *Kidney Int* 1985; **28**: 672–677.
647. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. *Am J Kidney Dis* 1999; **33**: 356–360.
648. Fattom A, Fuller S, Propst M *et al*. Safety and immunogenicity of a booster dose of *Staphylococcus aureus* types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. *Vaccine* 2004; **23**: 656–663.
649. Shinefield H, Black S, Fattom A *et al*. Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. *N Engl J Med* 2002; **346**: 491–496.
650. CDC immunization schedules. <http://www.cdc.gov/vaccines/schedules/index.html>.
651. American Academy of Pediatrics. Immunization: <http://www2.aap.org/immunization/>.
652. Neu AM. Immunizations in children with chronic kidney disease. *Pediatr Nephrol* 2012; **27**: 1257–1263.
653. Goldstein SL. Acute kidney injury in children: prevention, treatment and rehabilitation. *Contrib Nephrol* 2011; **174**: 163–172.
654. Goldstein SL. Acute kidney injury in children and its potential consequences in adulthood. *Blood Purif* 2012; **33**: 131–137.
655. Zappitelli M, Goldstein SL. Acute kidney failure in children. In: Jorres A, Ronco C, Kellum JA (eds.). *Management of Acute Kidney Problems*, Springer, 2010, pp 459–467.
656. Andreoli SP. Clinical evaluation of acute kidney injury in children. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds.). *Pediatric Nephrology*, (6th edn.). Springer, 2009, pp 1603–1618.
657. Zappitelli M, Goldstein SL. Management of acute kidney failure. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds.). *Pediatric Nephrology* (6th edn), Springer, 2009, pp 1619–1628.
658. Zappitelli M, Goldstein SL. Acute kidney injury: General aspects. In: Kiessling SG, Goebel J, Somers MJG (eds.). *Pediatric Nephrology in the ICU*, Springer, 2009, pp 85–97.
659. Arora P, Kausz AT, Obrador GT *et al*. Hospital utilization among chronic dialysis patients. *J Am Soc Nephrol* 2000; **11**: 740–746.
660. Khan SS, Kazmi WH, Abichandani R *et al*. Health care utilization among patients with chronic kidney disease. *Kidney Int* 2002; **62**: 229–236.
661. Becker BN, Coomer RW, Fotiadis C *et al*. Risk factors for hospitalization in well-dialyzed chronic hemodialysis patients. *Am J Nephrol* 1999; **19**: 565–570.
662. Popovic JR, Kozak LJ. National hospital discharge survey: annual summary, 1998. *Vital Health Stat* 13 2000; 1–194.
663. Rocco MV, Soucie JM, Reboussin DM *et al*. Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). *J Am Soc Nephrol* 1996; **7**: 889–896.
664. Thamer M, Ray NF, Fehrenbach SN *et al*. Relative risk and economic consequences of inpatient care among patients with renal failure. *J Am Soc Nephrol* 1996; **7**: 751–762.
665. Holland DC, Lam M. Predictors of hospitalization and death among predialysis patients: a retrospective cohort study. *Nephrol Dial Transplant* 2000; **15**: 650–658.
666. Culleton BF, Larson MG, Wilson PW *et al*. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 1999; **56**: 2214–2219.
667. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. *J Am Soc Nephrol* 1998; **9**: 531–42.

668. Drüeke TB, Locatelli F, Clyne N *et al.* Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 2006; **355**: 2071–2084.
669. Singh AK, Szczec L, Tang KL *et al.* Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 2006; **355**: 2085–2098.
670. De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal disease for nephrology consultation: a review of the literature. *J Nephrol* 2010; **23**: 399–407.
671. Navaneethan SD, Kandula P, Jeevanantham V *et al.* Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients. *Clin Nephrol* 2010; **73**: 260–267.
672. Navaneethan SD, Nigwekar S, Sengodan M *et al.* Referral to nephrologists for chronic kidney disease care: is non-diabetic kidney disease ignored? *Nephron Clin Pract* 2007; **106**: c113–118.
673. Chan MR, Dall AT, Fletcher KE *et al.* Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. *Am J Med* 2007; **120**: 1063–1070.
674. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. *Am J Med* 2011; **124**: 1073–1080.
675. McLaughlin K, Manns B, Culleton B *et al.* An economic evaluation of early versus late referral of patients with progressive renal insufficiency. *Am J Kidney Dis* 2001; **38**: 1122–1128.
676. Klebe B, Irving J, Stevens PE *et al.* The cost of implementing UK guidelines for the management of chronic kidney disease. *Nephrol Dial Transplant* 2007; **22**: 2504–2512.
677. Barakat AJ. Presentation of the child with renal disease and guidelines for referral to the pediatric nephrologist. *Int J Pediatr* 2012; 978673.
678. Barakat AJ, Chesney RW (eds.). *Pediatric Nephrology for Primary Care*. American Academy of Pediatrics: Illinois, 2009.
679. Kennedy SE, Bailey R, Kainer G. Causes and outcome of late referral of children who develop end-stage kidney disease. *J Paediatr Child Health* 2012; **48**: 253–258.
680. Boehm M, Winkelmayer WC, Arbeiter K *et al.* Late referral to paediatric renal failure service impairs access to pre-emptive kidney transplantation in children. *Arch Dis Child* 2010; **95**: 634–638.
681. Epping-Jordan JE, Pruitt SD, Bengoa R *et al.* Improving the quality of health care for chronic conditions. *Qual Saf Health Care* 2004; **13**: 299–305.
682. Ajarmeh S, Er L, Brin G *et al.* The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease. *Pediatr Nephrol* 2012; **27**: 1921–1927.
683. Menon S, Valentini RP, Kapur G *et al.* Effectiveness of a multidisciplinary clinic in managing children with chronic kidney disease. *Clin J Am Soc Nephrol* 2009; **4**: 1170–1175.
684. Korevaar JC, Jansen MA, Dekker FW *et al.* When to initiate dialysis: effect of proposed US guidelines on survival. *Lancet* 2001; **358**: 1046–1050.
685. Traynor JP, Simpson K, Geddes CC *et al.* Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. *J Am Soc Nephrol* 2002; **13**: 2125–2132.
686. Beddhu S, Samore MH, Roberts MS *et al.* Impact of timing of initiation of dialysis on mortality. *J Am Soc Nephrol* 2003; **14**: 2305–2312.
687. Clark WF, Na Y, Rosansky SJ *et al.* Association between estimated glomerular filtration rate at initiation of dialysis and mortality. *CMAJ* 2011; **183**: 47–53.
688. Hwang SJ, Yang WC, Lin MY *et al.* Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. *Nephrol Dial Transplant* 2010; **25**: 2616–2624.
689. Kazmi WH, Gilbertson DT, Obrador GT *et al.* Effect of comorbidity on the increased mortality associated with early initiation of dialysis. *Am J Kidney Dis* 2005; **46**: 887–896.
690. Lassalle M, Labeeuw M, Frimat L *et al.* Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. *Kidney Int* 2010; **77**: 700–707.
691. Sawhney S, Djurdjev O, Simpson K *et al.* Survival and dialysis initiation: comparing British Columbia and Scotland registries. *Nephrol Dial Transplant* 2009; **24**: 3186–3192.
692. Shiao CC, Huang JW, Chien KL *et al.* Early initiation of dialysis and late implantation of catheters adversely affect outcomes of patients on chronic peritoneal dialysis. *Perit Dial Int* 2008; **28**: 73–81.
693. Stel VS, Dekker FW, Ansell D *et al.* Residual renal function at the start of dialysis and clinical outcomes. *Nephrol Dial Transplant* 2009; **24**: 3175–3182.
694. Tang SC, Ho YW, Tang AW *et al.* Delaying initiation of dialysis till symptomatic uraemia—is it too late? *Nephrol Dial Transplant* 2007; **22**: 1926–1932.
695. Wilson B, Harwood L, Locking-Cusolito H *et al.* Optimal timing of initiation of chronic hemodialysis? *Hemodial Int* 2007; **11**: 263–269.
696. Wright S, Klausner D, Baird B *et al.* Timing of dialysis initiation and survival in ESRD. *Clin J Am Soc Nephrol* 2010; **5**: 1828–1835.
697. Cooper BA, Branley P, Bulfone L *et al.* A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med* 2010; **363**: 609–619.
698. Rosansky SJ, Eggers P, Jackson K *et al.* Early start of hemodialysis may be harmful. *Arch Intern Med* 2011; **171**: 396–403.
699. Harris A, Cooper BA, Li JJ *et al.* Cost-effectiveness of initiating dialysis early: a randomized controlled trial. *Am J Kidney Dis* 2011; **57**: 707–715.
700. Greenbaum LA, Schaefer F. The decision to initiate dialysis in a pediatric patient. In: Warady BA, Schaefer F, Alexander SR (eds). *Pediatric Dialysis*, Springer: New York, 2012, pp 85–100.
701. Kramer A, Stel VS, Tizard J *et al.* Characteristics and survival of young adults who started renal replacement therapy during childhood. *Nephrol Dial Transplant* 2009; **24**: 926–933.
702. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. *Am J Kidney Dis* 2003; **42**: 1239–1247.
703. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. *Kidney Int* 2006; **69**: 1621–1625.
704. Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. *Nephrol Dial Transplant* 2006; **21**: 3189–3195.
705. Murphy EL, Murtagh FE, Carey I *et al.* Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. *Nephron Clin Pract* 2009; **111**: c74–80.
706. Murtagh FE, Addington-Hall JM, Donohoe P *et al.* Symptom management in patients with established renal failure managed without dialysis. *EDTNA ERCA J* 2006; **32**: 93–98.
707. Murtagh FE, Addington-Hall JM, Edmonds PM *et al.* Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. *J Palliat Med* 2007; **10**: 1266–1276.
708. Saini T, Murtagh FE, Dupont PJ *et al.* Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. *Palliat Med* 2006; **20**: 631–636.
709. Temel JS, Greer JA, Muzikansky A *et al.* Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010; **363**: 733–742.
710. Chandna SM, Da Silva-Gane M, Marshall C *et al.* Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. *Nephrol Dial Transplant* 2011; **26**: 1608–1614.
711. Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2010; **5**: 195–204.
712. Davison SN, Murtagh FE, Higginson IJ. Methodological considerations for end-of-life research in patients with chronic kidney disease. *J Nephrol* 2008; **21**: 268–282.
713. De Biase V, Tobaldini O, Boaretti C *et al.* Prolonged conservative treatment for frail elderly patients with end-stage renal disease: the Verona experience. *Nephrol Dial Transplant* 2008; **23**: 1313–1317.
714. Ellam T, El-Kossi M, Prasanth KC *et al.* Conservatively managed patients with stage 5 chronic kidney disease—outcomes from a single center experience. *QJM* 2009; **102**: 547–554.
715. Germain MJ, Kurella Tamura M, Davison SN. Palliative care in CKD: the earlier the better. *Am J Kidney Dis* 2011; **57**: 378–380.
716. Murray AM, Arko C, Chen SC *et al.* Use of hospice in the United States dialysis population. *Clin J Am Soc Nephrol* 2006; **1**: 1248–1255.
717. Hearn J, Higginson IJ. Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. *Palliat Med* 1998; **12**: 317–332.
718. Higginson IJ, Wade AM, McCarthy M. Effectiveness of two palliative support teams. *J Public Health Med* 1992; **14**: 50–56.
719. Ventafridda V, De Conno F, Viganò A *et al.* Comparison of home and hospital care of advanced cancer patients. *Tumori* 1989; **75**: 619–625.
720. Wallston KA, Burger C, Smith RA *et al.* Comparing the quality of death for hospice and non-hospice cancer patients. *Med Care* 1988; **26**: 177–182.

721. Fassbender K, Smythe JG, Carson M, et al. *Report of the Institute for Public Economics Health Research Group to Alberta Health and Wellness: cost and utilization of health care services at end of life in Alberta, 1999–2002*. Edmonton, AB: University of Alberta. 2006.
722. Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol* 2010; **63**: 513–523.
723. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004; **328**: 1490.
724. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. *BMJ* 2008; **336**: 1049–1051.
725. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; **70**: 2058–2065.
726. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 2003; **12**: 18–23.
727. Shiffman RN, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. *Ann Intern Med* 2003; **139**: 493–498.
728. Institute of Medicine. *Finding What Works in Health Care: Standards for Systematic Reviews*. The National Academies Press: Washington, DC, 2011.
729. Institute of Medicine. *Clinical Practice Guidelines We Can Trust*. The National Academies Press: Washington, DC, 2011.